UNITED STATES SECURITIES AND

EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 24, 2007

PLURISTEM LIFE SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

001-31392

(Commission File Number)

98-0351734

(IRS Employer Identification No.)

MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905

(Address of principal executive offices and Zip Code)

011-972-4-850-1080

Registrant's telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.01. Completion of Acquisition or Disposition of Assets.

On May 22, 2007, we completed Assignment Agreements dated May 15, 2007 with each of Technion Research and Development Foundation Ltd., Shai Meretzki, Dr. Shoshana Merchav and Yeda Research and Development Ltd. (the “Assignors”), whereby the Assignors assigned to our company (the “Assignment”) the right to certain patent applications, patent license rights, patentable inventions, counterparts, re-issuances, re-examinations, continuations, continuations-in-art, divisions, extensions, whether or not filed, developed, derived or reduced to practice and any foreign counterparts thereof. The assignment completes the transfer of all intellectual property acquired from the Assignors in the Exclusive, World Wide Patent and Technology License and Assignment Agreement of May, 2003. In consideration of the Assignment, we paid an aggregate of $1,962,500 to the Assignors as follows:

 

 

 



 

- 2 -

 

 

 

Technion Research and Development Foundation Ltd.

$735,937

Yeda Research and Development Ltd.

$490,625

Dr. Shoshana Merchav

$367,969

Shai Meretzki

$367,969

Item 3.02. Unregistered Sales of Equity Securities.

On May 17, 2007, we closed a private placement consisting of 1,080,000,000 units of our securities at a price of $0.0125 per unit for gross proceeds of $13,500,000. Each unit consists of one common share in the capital of our company and one common share purchase warrant, with one such warrant entitling the holder to purchase one share of our common stock at a price of $0.025 per share for a period of five years. Of the $13,500,000, we have received all but $5,000,000, which is being paid in monthly installments over 10 months starting six months from closing

We issued the securities to 16 non-U.S. persons (as that term is defined in Regulation S of the Securities Act of 1933) in an offshore transaction relying on Regulation S and/or Section 4(2) of the Securities Act of 1933 and to 37 US persons relying on Rule 506 of Regulation D promulgated under the 1933 Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective May 17, 2007, Mark Germain was appointed a director of our company.

Item 7.01. Regulation FD Disclosure.

On January 24, 2007, we adopted an amended stock option plan (the “Amended 2005 Option Plan”) for our directors and employees, reserving a total of 280,000,000 shares of our common stock for issuance pursuant to grants made under the Amended 2005 Option Plan.

Item 9.01. Financial Statements and Exhibits.

99.1

Amended 2005 Option Plan.

99.2

List of Subscribers.

10.1         Form of Assignment Agreement dated May 15, 2007 entered into with Technion Research and Development Foundation Ltd., Shai Meretzki and Dr. Shoshana Merchav.

10.2         Form of Assignment Agreement dated May 15, 2007 entered into with Yeda Research and Development Ltd.

10.3         Form of Subscription Agreement.

 

 

 



 

- 3 -

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM LIFE SYSTEMS, INC.

By: /s/ Zami Aberman

 

Zami Aberman, Chief Executive Officer

Date: May 24, 2007

 

 

 

 

 

PLURISTEM LIFE SYSTEMS, INC.

AMENDED 2005 STOCK OPTION PLAN

This Amended 2005 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Pluristem Life Systems, Inc., a corporation formed under the laws of the State of Nevada (the "Corporation"). Stock options granted under this Plan will include:

 

(a)

stock options that qualify under Section 422 of the Internal Revenue Code of 1986, as amended (the "Code"), which will be referred to in this Plan as "Incentive Stock Options";

 

(b)

stock options that qualify under Section 102 of the Israeli Tax Ordinance (New Version) 1961, as amended and the rules and regulations promulgated thereunder (the "Ordinance"), which will be referred to in this Plan as "Section 102 Options";

 

(c)

stock options that do not qualify under Section 422 of the Code , which will be referred to in this Plan as "Non-Qualified Stock Options"; and

 

(d)

Section 3(i) Options, being options under Section 3(i) of the Ordinance to consultants and Controlling Shareholders that are excluded from the term “Israeli Employee” as defined in Section 3.1 herein.

Incentive Stock Options, Section 102 Options, Non-Qualified Stock Options and Section 3(i) Options granted under this Plan are collectively referred to as "Options".

1.

PURPOSE

1.1                          The purpose of this Plan is to retain the services of valued key employees and consultants of the Corporation and such other persons as the Plan Administrator (as hereinafter defined) shall select in accordance with Section 3 below, and to encourage such persons to acquire a greater proprietary interest in the Corporation, thereby strengthening their incentive to achieve the objectives of the shareholders of the Corporation, and to serve as an aid and inducement in the hiring of new employees and to provide an equity incentive to consultants and other persons selected by the Plan Administrator.

1.2                          This Plan shall at all times be subject to all legal requirements relating to the administration of stock option plans, if any, under applicable corporate laws, applicable United States federal and state securities laws, the Code, applicable Israeli tax laws, Israeli securities laws, Israeli corporate laws, Israeli foreign exchange control laws the rules of any applicable stock exchange or stock quotation system, and the rules of any other foreign jurisdiction applicable to Options granted to residents therein (collectively, the "Applicable Laws").

2.

ADMINISTRATION

2.1                          This Plan shall be administered initially by the board of directors of the Corporation (the "Board"), except that the Board may, in its discretion, establish a committee

 

 



 

- 2 -

 

 

composed of two (2) or more members of the Board or two (2) or more other persons to administer the Plan, which committee (the "Committee") may be an executive, compensation or other committee, including a separate committee especially created for this purpose. The Board or, if applicable, the Committee is referred to herein as the "Plan Administrator".

2.2                          If and so long as the Common Shares is registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the Corporation wishes to grant Incentive Stock Options, then the Board shall consider in selecting the Plan Administrator and the membership of any Committee, with respect to any persons subject or likely to become subject to Section 16 of the Exchange Act, the provisions regarding (a) "outside directors" as contemplated by Section 162(m) of the Code, and (b) "Non-Employee Directors" as contemplated by Rule 16b-3 under the Exchange Act.

2.3                          The Committee shall have the powers and authority vested in the Board hereunder (including the power and authority to interpret any provision of the Plan or of any Option). The members of any such Committee shall serve at the pleasure of the Board. A majority of the members of the Committee shall constitute a quorum, and all actions of the Committee shall be taken by a majority of the members present. Any action may be taken by a written instrument signed by all of the members of the Committee and any action so taken shall be fully effective as if it had been taken at a meeting.

2.4                          Subject to the provisions of this Plan and any Applicable Laws, and with a view to accomplishing the purpose of the Plan, the Plan Administrator shall have sole authority, in its absolute discretion, to:

 

(a)

construe and interpret the terms of the Plan and any Option granted pursuant to this Plan;

 

(b)

define the terms used in the Plan;

 

(c)

prescribe, amend and rescind the rules and regulations relating to this Plan;

 

(d)

correct any defect, supply any omission or reconcile any inconsistency in this Plan;

 

(e)

grant Options under this Plan, except grants to directors, the CEO, the CFO and the CTO of the Corporation, which will be granted by the Board as a whole;

 

(f)

determine the individuals to whom Options shall be granted under this Plan and whether the Option is granted as an Incentive Stock Option, Section 102 Option, a Non-Qualified Stock Option or Section 3(i) Option;

 

(g)

make an election under Section 102(b)(1) or (2) of the Ordinance;

 

(h)

determine the time or times at which Options shall be granted under this Plan;

 

 



 

- 3 -

 

 

 

(i)

determine the number of Common Shares subject to each Option, the exercise price of each Option, the duration of each Option and the times at which each Option shall become exercisable;

 

(j)

determine all other terms and conditions of the Options; and

 

(k)

make all other determinations and interpretations necessary and advisable for the administration of the Plan.

2.5                          All decisions, determinations and interpretations made by the Plan Administrator shall be binding and conclusive on all participants in the Plan and on their legal representatives, heirs and beneficiaries.

3.

ELIGIBILITY

3.1

Definitions. In this agreement:

Affiliate ” means any “employing company” within the meaning of Section 102(a) of the Ordinance.

Controlling Shareholder ” shall have the meaning ascribed to it in Section 32(9) of the Ordinance."

“Israeli Employee” means a person who is employed by the Corporation or its Affiliates in Israel , including an individual who is serving as a director or an office holder, but excluding a Controlling Shareholder.

“Related Corporation " means any corporation (other than the Corporation) that is a "Parent Corporation" of the Corporation or "Subsidiary Corporation" of the Corporation, as those terms are defined in Sections 424(e) and 424(f), respectively, of the Code (or any successor provisions) and the regulations thereunder (as amended from time to time).

3.2                          Incentive Stock Options may be granted to any individual who, at the time such Option is granted, is an employee of the Corporation or any Related Corporation (as hereinafter defined) (an "Employee").

3.3                          Non-Qualified Stock Options may be granted to Employees, and to such other persons who are not Employees as the Plan Administrator shall select, subject to any Applicable Laws.

3.4                          Section 102 Options may be granted to Israeli Employees in accordance with Section 4 herein.

3.5                          Section 3(i) Options may be granted to consultants and Controlling Shareholders that do not qualify as Israeli Employees.

3.6                          Options may be granted in substitution for outstanding Options of another corporation in connection with the merger, consolidation, acquisition of property or stock or

 

 



 

- 4 -

 

 

other reorganization between such other corporation and the Corporation or any subsidiary of the Corporation. Options also may be granted in exchange for outstanding Options.

3.7                          Any person to whom an Option is granted under this Plan is referred to as an "Optionee". Any person who is the owner of an Option is referred to as a "Holder".

4.

DESIGNATION OF OPTIONS PURSUANT TO SECTION 102 (RELEVANT ONLY TO ISRAELI EMPLOYEES)

4.1                          The Corporation may designate Section 102 Options granted to Israeli Employees pursuant to Section 102 of the Ordinance as Unapproved 102 Options (means an Option granted pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee) or Approved 102 Options (means an Option granted pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit of the Optionee).

4.2                          The grant of Approved 102 Options shall be made under this Plan adopted by the Board, and shall be conditioned upon the approval of this Plan by the Israeli Tax Authorities (the " ITA ").

4.3                          Approved 102 Option may either be classified as Capital Gain Option (" CGO ") or Ordinary Income Option (" OIO ").

4.4                          Approved 102 Option elected and designated by the Corporation to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) shall be referred to herein as CGO .

4.5                          Approved 102 Option elected and designated by the Corporation to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) shall be referred to herein as OIO .

4.6                          The Corporation's election of the type of Approved 102 Options as CGO or OIO granted to Employees (the " Election "), shall be appropriately filed with the ITA before the Date of Grant of an Approved 102 Option. Such Election shall become effective beginning the first Date of Grant of an Approved 102 Option under this Plan and shall remain in effect at least until the end of the year following the year during which the Corporation first granted Approved 102 Options. The Election shall obligate the Corporation to grant only the type of Approved 102 Option it has elected, and shall apply to all Optionees who were granted Approved 102 Options during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Ordinance. For the avoidance of doubt, such Election shall not prevent the Corporation from granting Unapproved 102 Options simultaneously.

4.7                          All Approved 102 Options must be held in trust by a Trustee (means any entity appointed by the Corporation to serve as a trustee and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance, as described in Section 5 below (the “ Trustee ”)).

 

 



 

- 5 -

 

 

4.8                          For the avoidance of doubt, the designation of Unapproved 102 Options and Approved 102 Options shall be subject to the terms and conditions set forth in Section 102 of the Ordinance and the regulations promulgated thereunder.

4.9                          With regards to Approved 102 Options, the provisions of the Plan and/or the Option Agreement shall be subject to the provisions of Section 102 and the Tax Assessing Officer's permit, and the said provisions and permit shall be deemed an integral part of the Plan and of the Option Agreement. Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the Plan or the Option Agreement, shall be considered binding upon the Corporation and the Optionees.

5.

TRUSTEE

5.1                          Approved 102 Options which shall be granted under the Plan and/or any Shares allocated or issued upon exercise of such Approved 102 Options and/or other shares received subsequently following any realization of rights, including, without limitation, bonus shares, shall be allocated or issued to the Trustee and held for the benefit of the Optionees for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the " Holding Period "). In the case the requirements for Approved 102 Options are not met, then the Approved 102 Options may be treated as Unapproved 102 Options, all in accordance with the provisions of Section 102 and regulations promulgated thereunder.

5.2                          Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or issued upon exercise of Approved 102 Options prior to the full payment of the Optionee's tax liabilities arising from Approved 102 Options which were granted to him and/or any Shares allocated or issued upon exercise of such Options.

5.3                          Upon receipt of Approved 102 Option, the Optionee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the Plan, or any Approved 102 Option or Share granted to him thereunder.

5.4                          With respect to any Approved 102 Option, subject to the provisions of Section 102 and any rules or regulation or orders or procedures promulgated thereunder, an Optionee shall not sell or release from trust any Share received upon the exercise of an Approved 102 Option and/or any share received subsequently following any realization of rights, including without limitation, bonus shares, until the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 of the Ordinance and under any rules or regulation or orders or procedures promulgated thereunder shall apply to and shall be borne by such Optionee

5.5                          With respect to all Shares (but excluding, for avoidance of any doubt, any unexercised Options) allocated or issued upon the exercise of Options purchased by the Optionee and held by the Optionee or by the Trustee, as the case may be, the Optionee shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the

 

 



 

- 6 -

 

 

Corporation's incorporation documents (and all amendments thereto) and subject to any applicable taxation on distribution of dividends, and when applicable subject to the provisions of Section 102.

6.

STOCK

6.1                          The Plan Administrator is authorized to grant Options to acquire up to a total of 280,000,000 Common Shares. The number of Common Shares with respect to which Options may be granted hereunder is subject to adjustment as set forth in Section 7.1(m) hereof. In the event that any outstanding Option expires or is terminated for any reason, the Common Shares allocable to the unexercised portion of such Option may again be subject to an Option granted to the same Optionee or to a different person eligible under Section 3 of this Plan; provided however, that any cancelled Options will be counted against the maximum number of Common Shares with respect to which Options may be granted to any particular person as set forth in Section 3 hereof.

7.

TERMS AND CONDITIONS OF OPTIONS

7.1                          Each Option granted under this Plan shall be evidenced by a written agreement approved by the Plan Administrator (each, an "Agreement"). Agreements may contain such provisions, not inconsistent with this Plan or any Applicable Laws, as the Plan Administrator in its discretion may deem advisable. All Options also shall comply with the following requirements:

 

(a)

Number of Shares and Type of Option

Each Agreement shall state the number of Common Shares to which it pertains and whether the Option is intended to be an Incentive Stock Option, Section 102 Option (CGO or OIO) or a Non-Qualified Stock Option; provided that :

 

(i)

the number of Common Shares that may be reserved pursuant to the exercise of Options granted to any person shall not exceed 5% of the issued and outstanding Common Shares of the Corporation;

 

(ii)

in the absence of action to the contrary by the Plan Administrator in connection with the grant of an Option, all Options shall be Non-Qualified Stock Options, Unapproved 102 Options or Section 3(i) Options, as the case maybe;

 

(iii)

the aggregate fair market value (determined at the Date of Grant, as defined below) of the Common Shares with respect to which Incentive Stock Options are exercisable for the first time by the Optionee during any calendar year (granted under this Plan and all other Incentive Stock Option plans of the Corporation, a Related Corporation or a predecessor corporation) shall not exceed U.S.$100,000, or such other limit as may be prescribed by the Code as it may be amended from time to time (the "Annual Limit"); and

 

 



 

- 7 -

 

 

 

(iv)

any portion of an Option which exceeds the Annual Limit shall not be void but rather shall be a Non-Qualified Stock Option.

 

(b)

Date of Grant

Each Agreement shall state the date the Plan Administrator has deemed to be the effective date of the Option for purposes of this Plan (the "Date of Grant"). Option Price

 

(c)

Exercise Price

Each Agreement shall state the price per Common Share at which it is exercisable. The Plan Administrator shall act in good faith to establish the exercise price in accordance with Applicable Laws; provided that:

 

(i)

the per share exercise price for an Incentive Stock Option or any Option granted to a "covered employee" as such term is defined for purposes of Section 162(m) of the Code shall not be less than the fair market value per Common Share at the Date of Grant as determined by the Plan Administrator in good faith;

 

(ii)

with respect to Incentive Stock Options granted to greater-than-ten percent (>10%) shareholders of the Corporation (as determined with reference to Section 424(d) of the Code), the exercise price per share shall not be less than one hundred ten percent (110%) of the fair market value per Common Share at the Date of Grant as determined by the Plan Administrator in good faith; and

 

(iii)

Options granted in substitution for outstanding options of another corporation in connection with the merger, consolidation, acquisition of property or stock or other reorganization involving such other corporation and the Corporation or any subsidiary of the Corporation may be granted with an exercise price equal to the exercise price for the substituted option of the other corporation, subject to any adjustment consistent with the terms of the transaction pursuant to which the substitution is to occur.

 

(iv)

solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, if at the date of grant the Corporation's shares are listed on any established stock exchange or a national market system or if the Corporation's shares will be registered for trading within ninety (90) days following the date of grant of the CGOs, the fair market value of the Shares at the date of grant shall be determined in accordance with the average value of the Corporation's shares on the thirty (30) trading days preceding the date of grant or on the thirty (30) trading days following the date of registration for trading, as the case may be.

 

(d)

Duration of Options

 

 



 

- 8 -

 

 

At the time of the grant of the Option, the Plan Administrator shall designate, subject to Section 7.1(g) below, the expiration date of the Option, which date shall not be later than 10 years from the Date of Grant; provided , that the Plan Administrator decided otherwise in specific option agreements or, that the expiration date of any Incentive Stock Option granted to a greater-than-ten percent (>10%) shareholder of the Corporation (as determined with reference to Section 424(d) of the Code) shall not be later than five (5) years from the Date of Grant. In the absence of action to the contrary by the Plan Administrator in connection with the grant of a particular Option, and except in the case of Incentive Stock Options as described above, all Options granted under this Section 7 shall expire 10 years from the Date of Grant.

 

(e)

Vesting Schedule

No Option shall be exercisable until it has vested. The vesting schedule for each Option shall be specified by the Plan Administrator at the time of grant of the Option prior to the provision of services with respect to which such Option is granted.; provided that if no vesting schedule is specified at the time of grant, the Option shall vest as follows:

 

(i)

on the six month anniversary of the Date of Grant, the Option shall vest and shall become exercisable with respect to 25% of the Common Stock to which it pertains;

 

(ii)

on the seven month and each successive month anniversary to and including the twenty three month anniversary, the Option shall vest and become exercisable with respect to an additional four (4%) percent of the Common Stock to which it pertains ; and

 

(iii)

on the twenty-four month anniversary of the Date of Grant, the Option shall vest and shall become exercisable with respect to balance of the Common Stock to which it pertains.

The Plan Administrator may specify a vesting schedule for all or any portion of an Option based on the achievement of performance objectives established in advance of the commencement by the Optionee of services related to the achievement of the performance objectives. Performance objectives shall be expressed in terms of objective criteria, including but not limited to, one or more of the following: return on equity, return on assets, share price, market share, sales, earnings per share, costs, net earnings, net worth, inventories, cash and cash equivalents, gross margin or the Corporation's performance relative to its internal business plan. Performance objectives may be in respect of the performance of the Corporation as a whole (whether on a consolidated or unconsolidated basis), a Related Corporation, or a subdivision, operating unit, product or product line of either of the foregoing. Performance objectives may be absolute or relative and may be expressed in terms of a progression or a range. An Option that is exercisable (in full or in part) upon the achievement of one or more performance objectives may be exercised only

 

 



 

- 9 -

 

 

following written notice to the Optionee and the Corporation by the Plan Administrator that the performance objective has been achieved.

 

(f)

Acceleration of Vesting

The vesting of one or more outstanding Options may be accelerated by the Plan Administrator at such times and in such amounts as it shall determine in its sole discretion.

 

(g)

Term of Option

 

(i)

Vested Options shall terminate, to the extent not previously exercised, upon the occurrence of the first of the following events:

 

A.

the expiration of the Option, as designated by the Plan Administrator in accordance with Section 7.1(d) above;

 

B.

the date an Optionee receives a notice of his or her termination of employment or contractual relationship with the Corporation or any Related Corporation for Cause (as hereinafter defined); or

 

C.

the expiration of five (5) years, unless otherwise determined in specific agreements by the Plan Administrator, from the date of an Optionee's termination of employment or contractual relationship with the Corporation or any Related Corporation for any reason whatsoever other than Cause, but including death or disability, unless, in the case of a Non-Qualified Stock Option, Section 102 Option or Section 3(i) Option, the exercise period is extended by the Plan Administrator until a date not later than the expiration date of the Option;

 

(ii)

Notwithstanding Section 7.1(g)(i) above, any vested Options which have been granted to an Optionee in the Optionee's capacity as a director of the Corporation or any Related Corporation shall terminate upon the occurrence of the first of the following events:

 

A.

the event specified in Section 7.1(g)(i)A above;

 

B.

the expiration of five (5) years, unless otherwise determined in specific agreements by the Plan Administrator, from the date the Optionee ceases to serve as a director of the Corporation or Related Corporation, as the case may be, unless, in the case of a Non-Qualified Stock Option or Section 102 Option, the exercise period is extended by the Plan Administrator until a date not later than the expiration date of the Option.

 

(iii)

Upon the death of an Optionee, any vested option still in force and unexpired may be exercised by the person or persons to whom such

 

 



 

- 10 -

 

 

Optionee's rights under such Option shall pass by the Optionee's will or by the laws of descent and distribution of the Optionee's domicile at the time of death, within a period of twelve (12) months after the date of such termination.

 

(iv)

For purposes of the Plan, unless otherwise defined in the Agreement, termination for "Cause" shall mean such termination is for ‘cause' as such term is expressly defined in a then-effective written agreement between the Optionee and the Corporation or any Related Corporation, or in the absence of such then-effective written agreement and in the case of an Employee or an Israeli Employee, termination for the following reasons (i) conviction of any felony involving moral turpitude or affecting the Corporation; (ii) any refusal to carry out a reasonable directive of the chief executive officer, the Board or the Optionee's direct supervisor, which involves the business of the Corporation or its Related Corporation and was capable of being lawfully performed; (iii) embezzlement of funds of the Corporation or its Related Corporation; (iv) any breach of the Optionee's fiduciary duties or duties of care of the Corporation; including without limitation disclosure of confidential information of the Corporation; and (v) any conduct (other than conduct in good faith) reasonably determined by the Board to be materially detrimental to the Corporation. Unless accelerated in accordance with Section 7.1(f) above, unvested Options shall terminate immediately upon termination of employment or contractual relationship of an Optionee with the Corporation or a Related Corporation, or termination of an Optionee's services as a director of the Corporation or a Related Corporation, for any reason whatsoever, including death or disability.

 

(v)

For purposes of this Plan, transfer of employment between or among the Corporation and/or any Related Corporation shall not be deemed to constitute a termination of employment with the Corporation or any Related Corporation. Employment shall be deemed to continue while the Optionee is on military leave, sick leave or other bona fide leave of absence (as determined by the Plan Administrator). The foregoing notwithstanding, employment shall not be deemed to continue beyond the first ninety (90) days of such leave, unless otherwise determined in specific agreements by the Plan Administrator and unless the Optionee's re-employment rights are guaranteed by statute or by contract.

 

(h)

Exercise of Options

 

(i)

Options shall be exercisable, in full or in part, at any time after vesting, until termination. If less than all of the Common Shares included in the vested portion of any Option are purchased, the remainder may be purchased at any subsequent time prior to the expiration of the Option term. Only whole Common Shares may be issued pursuant to an Option,

 

 



 

- 11 -

 

 

and to the extent that an Option covers less than one (1) Common Share, it is unexercisable.

 

(ii)

Options or portions thereof may be exercised by giving written notice to the Corporation, in such form and method as may be determined by the Corporation and when applicable, by the Trustee in accordance with the requirements of Section 102 of the Ordinance, which notice shall specify the number of Common Shares to be purchased, and be accompanied by payment in the amount of the aggregate exercise price for the Common Shares so purchased, which payment shall be in the form specified in Section 7.1(i) below. The Corporation shall not be obligated to issue, transfer or deliver a certificate representing Common Shares to the Holder of any Option, until provision has been made by the Holder, to the satisfaction of the Corporation, for the payment of the aggregate exercise price for all Common Shares for which the Option shall have been exercised and for satisfaction of any tax withholding obligations associated with such exercise. During the lifetime of an Optionee, Options are exercisable only by the Optionee.

 

(iii)

For Israeli Employees the above mentioned in section h(ii) is subject to section 102 and the trust mechanism as defined in section 5 of this Plan.

With respect to Unapproved 102 Option, if the Optionee ceases to be employed by the Corporation or any Afffiliate, the Optionee shall extend to the Corporation and/or its Affiliate a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.

 

(i)

Payment upon Exercise of Option

Upon the exercise of any Option, the aggregate exercise price shall be paid to the Corporation in cash or by certified or cashier's check. In addition, if pre-approved in writing by the Plan Administrator who may arbitrarily withhold consent, the Holder may pay for all or any portion of the aggregate exercise price by complying with one or more of the following alternatives:

 

(i)

by delivering to the Corporation Common Shares previously held by such Holder, or by the Corporation withholding Common Shares otherwise deliverable pursuant to exercise of the Option, which Common Shares received or withheld shall have a fair market value at the date of exercise (as determined by the Plan Administrator) equal to the aggregate exercise price to be paid by the Optionee upon such exercise;

 

(ii)

by delivering a properly executed exercise notice together with irrevocable instructions to a broker promptly to sell or margin a sufficient portion of

 

 



 

- 12 -

 

 

the Common Shares and deliver directly to the Corporation the amount of sale or margin loan proceeds to pay the exercise price; or

 

(iii)

by complying with any other payment mechanism approved by the Plan Administrator at the time of exercise.

 

(j)

No Rights as a Shareholder

A Holder shall have no rights as a shareholder of the Corporation with respect to any Common Shares covered by an Option until such Holder becomes a record holder of such Common Shares, irrespective of whether such Holder has given notice of exercise. Subject to the provisions of Section 7.1(m) hereof, no rights shall accrue to a Holder and no adjustments shall be made on account of dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions or other rights declared on, or created in, the Common Shares for which the record date is prior to the date the Holder becomes a record holder of the Common Shares covered by the Option, irrespective of whether such Holder has given notice of exercise. In case of Options and Common Shares held by the Trustee, subject to the provisions of Section 5 of the Plan.

 

(k)

Non-transferability of Options

Options granted under this Plan and the rights and privileges conferred by this Plan may not be transferred, assigned, pledged or hypothecated in any manner (whether by operation of law or otherwise) other than by will, by applicable laws of descent and distribution, and shall not be subject to execution, attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of any Option or of any right or privilege conferred by this Plan contrary to the provisions hereof, or upon the sale, levy or any attachment or similar process upon the rights and privileges conferred by this Plan, such Option shall thereupon terminate and become null and void.

As long as Options and/or Common Shares are held by the Trustee on behalf of the Optionee, all rights of the Optionee over the Common Shares are personal, can not be transferred, assigned, pledged or mortgaged, other than by will or pursuant to the laws of descent and distribution.

 

(l)

Securities Regulation and Tax Withholding

 

(i)

Common Shares shall not be issued with respect to an Option unless the exercise of such Option and the issuance and delivery of such Common Shares shall comply with all Applicable Laws, and such issuance shall be further subject to the approval of counsel for the Corporation with respect to such compliance, including the availability of an exemption from prospectus and registration requirements for the issuance and sale of such Common Shares. The inability of the Corporation to obtain from any regulatory body the authority deemed by the Corporation to be necessary for the lawful issuance and sale of any Common Shares under this Plan, or

 

 



 

- 13 -

 

 

the unavailability of an exemption from prospectus and registration requirements for the issuance and sale of any Common Shares under this Plan, shall relieve the Corporation of any liability with respect to the non-issuance or sale of such Common Shares.

 

(ii)

As a condition to the exercise of an Option, the Plan Administrator may require the Holder to represent and warrant in writing at the time of such exercise that the Common Shares are being purchased only for investment and without any then-present intention to sell or distribute such Common Shares. If necessary under Applicable Laws, the Plan Administrator may cause a stop-transfer order against such Common Shares to be placed on the stock books and records of the Corporation, and a legend indicating that the Common Shares may not be pledged, sold or otherwise transferred unless an opinion of counsel is provided stating that such transfer is not in violation of any Applicable Laws, may be stamped on the certificates representing such Common Shares in order to assure an exemption from registration. The Plan Administrator also may require such other documentation as may from time to time be necessary to comply with applicable securities laws. THE CORPORATION HAS NO OBLIGATION TO UNDERTAKE REGISTRATION OF OPTIONS OR THE COMMON SHARES ISSUABLE UPON THE EXERCISE OF OPTIONS.

 

(iii)

The Holder shall pay to the Corporation by certified or cashier's check, promptly upon exercise of an Option or, if sooner or later, the date that the amount of such obligations becomes determinable, all applicable federal, state, local and foreign withholding taxes that the Plan Administrator or the Trustee, in their discretion, subject to section 102 in case of Israeli Employees, determines to result upon exercise of an Option or from a transfer or other disposition of Common Shares acquired upon exercise of an Option or otherwise related to an Option or Common Shares acquired in connection with an Option. Furthermore, the Holder shall agree to indemnify the Corporation and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Holder. Upon approval of the Plan Administrator, a Holder may satisfy such obligation by complying with one or more of the following alternatives selected by the Plan Administrator:

 

A.

by delivering to the Corporation Common Shares previously held by such Holder or by the Corporation withholding Common Shares otherwise deliverable pursuant to the exercise of the Option, which Common Shares received or withheld shall have a fair market value (as determined by the Plan Administrator) equal to the minimum mandatory withholding tax obligations arising as a result of such exercise, transfer or other disposition; or

 

 



 

- 14 -

 

 

 

B.

by complying with any other payment mechanism approved by the Plan Administrator from time to time.

 

 

(iv)

The issuance, transfer or delivery of certificates representing Common Shares pursuant to the exercise of Options may be delayed, at the discretion of the Plan Administrator, until the Plan Administrator is satisfied that the applicable requirements of all Applicable Laws and the withholding provisions of the Code and/or the Ordinance have been met and that the Holder has paid or otherwise satisfied any withholding tax obligation as described in Section 7.1(l)(iii) above.

 

(m)

Adjustments Upon Changes In Capitalization

 

(i)

The aggregate number and class of shares for which Options may be granted under this Plan, the number and class of shares covered by each outstanding Option, and the exercise price per share thereof (but not the total price), and each such Option, shall all be proportionately adjusted for any increase or decrease in the number of issued Common Shares of the Corporation resulting from:

 

A.

a subdivision or consolidation of Common Shares or any like capital adjustment, or

 

B.

the issuance of any Common Shares, or securities exchangeable for or convertible into Common Shares, to the holders of all or substantially all of the outstanding Common Shares by way of a stock dividend (other than the issue of Common Shares, or securities exchangeable for or convertible into Common Shares, to holders of Common Shares pursuant to their exercise of options to receive dividends in the form of Common Shares, or securities convertible into Common Shares, in lieu of dividends paid in the ordinary course on the Common Shares).

 

(ii)

Except as provided in Section 7.1(m)(iii) hereof, upon a merger (other than a merger of the Corporation in which the holders of Common Shares immediately prior to the merger have the same proportionate ownership of common shares in the surviving corporation immediately after the merger), consolidation, acquisition of property or stock, separation, reorganization (other than a mere re-incorporation or the creation of a holding Corporation) or liquidation of the Corporation, as a result of which the shareholders of the Corporation, receive cash, shares or other property in exchange for or in connection with their Common Shares, any Option granted hereunder shall terminate, but the Holder shall have the right to exercise such Holder's Option immediately prior to any such merger, consolidation, acquisition of property or shares, separation,

 

 



 

- 15 -

 

 

reorganization or liquidation, and to be treated as a shareholder of record for the purposes thereof, to the extent the vesting requirements set forth in the Option agreement have been satisfied.

 

(iii)

If the shareholders of the Corporation receive shares in the capital of another corporation ("Exchange Shares") in exchange for their Common Shares in any transaction involving a merger (other than a merger of the Corporation in which the holders of Common Shares immediately prior to the merger have the same proportionate ownership of Common Shares in the surviving corporation immediately after the merger), consolidation, acquisition of property or shares, separation or reorganization (other than a mere re-incorporation or the creation of a holding Corporation), all Options granted hereunder shall be converted into options to purchase Exchange Shares unless the Corporation and the corporation issuing the Exchange Shares, in their sole discretion, determine that any or all such Options granted hereunder shall not be converted into options to purchase Exchange Shares but instead shall terminate in accordance with, and subject to the Holder's right to exercise the Holder's Options pursuant to, the provisions of Section 7.1(m)(ii). The amount and price of converted options shall be determined by adjusting the amount and price of the Options granted hereunder in the same proportion as used for determining the number of Exchange Shares the holders of the Common Shares receive in such merger, consolidation, acquisition or property or stock, separation or reorganization. Unless accelerated by the Board, the vesting schedule set forth in the option agreement shall continue to apply to the options granted for the Exchange Shares.

 

(iv)

In the event of any adjustment in the number of Common Shares covered by any Option, any fractional shares resulting from such adjustment shall be disregarded and each such Option shall cover only the number of full shares resulting from such adjustment.

 

(v)

All adjustments pursuant to Section 7.1(m) shall be made by the Plan Administrator, and its determination as to what adjustments shall be made, and the extent thereof, shall be final, binding and conclusive.

 

(vi)

The grant of an Option shall not affect in any way the right or power of the Corporation to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge, consolidate or dissolve, to liquidate or to sell or transfer all or any part of its business or assets.

8.

EFFECTIVE DATE; AMENDMENT; SHAREHOLDER APPROVAL

8.1                          Options may be granted by the Plan Administrator from time to time on or after the date on which this Plan is adopted by the Board (the " Effective Date "). In case of the Israeli Optionees, Approved 102 Options will be granted only after the lapse of at least 30 days

 



 

- 16 -

 

 

following the date in which the Plan and the relevant forms will be submitted to the tax authorities as detailed in Section 4.6 above.

8.2                          Unless sooner terminated by the Board, this Plan shall terminate on the tenth anniversary of the Effective Date. No Option may be granted after such termination or during any suspension of this Plan.

8.3                          Any Incentive Stock Options granted by the Plan Administrator prior to the ratification of this Plan by the shareholders of the Corporation shall be granted subject to approval of this Plan by the holders of a majority of the Corporation's outstanding voting shares, voting either in person or by proxy at a duly held shareholders' meeting within twelve (12) months before or after the Effective Date. If such shareholder approval is sought and not obtained, all Incentive Stock Options granted prior thereto and thereafter shall be considered Non-Qualified Stock Options and any Options granted to Covered Employees will not be eligible for the exclusion set forth in Section 162(m) of the Code with respect to the deductibility by the Corporation of certain compensation.

9.

NO OBLIGATIONS TO EXERCISE OPTION

The grant of an Option shall impose no obligation upon the Optionee to exercise such Option.

10.

NO RIGHT TO OPTIONS OR TO EMPLOYMENT

Whether or not any Options are to be granted under this Plan shall be exclusively within the discretion of the Plan Administrator, and nothing contained in this Plan shall be construed as giving any person any right to participate under this Plan. The grant of an Option shall in no way constitute any form of agreement or understanding binding on the Corporation or any Related Corporation, express or implied, that the Corporation or any Related Corporation will employ or contract with an Optionee for any length of time, nor shall it interfere in any way with the Corporation's or, where applicable, a Related Corporation's right to terminate Optionee's employment at any time, which right is hereby reserved.

11.

APPLICATION OF FUNDS

The proceeds received by the Corporation from the sale of Common Shares issued upon the exercise of Options shall be used for general corporate purposes, unless otherwise directed by the Board.

12.

INDEMNIFICATION OF PLAN ADMINISTRATOR

In addition to all other rights of indemnification they may have as members of the Board, members of the Plan Administrator shall be indemnified by the Corporation for all reasonable expenses and liabilities of any type or nature, including attorneys' fees, incurred in connection with any action, suit or proceeding to which they or any of them are a party by reason of, or in connection with, this Plan or any Option granted under this Plan, and against all amounts paid by them in settlement thereof (provided that such settlement is approved by independent legal counsel selected by the Corporation), except to the extent that such expenses relate to matters for which it is adjudged that such Plan Administrator member is liable for wilful misconduct;

 

 



 

- 17 -

 

 

provided, that within fifteen (15) days after the institution of any such action, suit or proceeding, the Plan Administrator member involved therein shall, in writing, notify the Corporation of such action, suit or proceeding, so that the Corporation may have the opportunity to make appropriate arrangements to prosecute or defend the same.

13.

AMENDMENT OF PLAN

The Plan Administrator may, at any time, modify, amend or terminate this Plan or modify or amend Options granted under this Plan, including, without limitation, such modifications or amendments as are necessary to maintain compliance with the Applicable Laws. The Plan Administrator may condition the effectiveness of any such amendment on the receipt of shareholder approval at such time and in such manner as the Plan Administrator may consider necessary for the Corporation to comply with or to avail the Corporation and/or the Optionees of the benefits of any securities, tax, market listing or other administrative or regulatory requirements.

Effective Date: September 18, 2006

 

 

 

D/ljm/719792.4

 

 

 

Pluristem Life Systems Inc.

 

List of Investors

 

AMY GANZ

AVINOAM KADORI

AVNER AND MICHAL STEPAK

BARRY HONIG

BENJAMIN BLECH

BRS ENERGY INVESTMENTS LLC

CAPELA OVERSEAS LTD

CHARLA CROITOROO

CRAIG H. BIRD

DAB HOLDINGS

DIANE TURK

ELINOR C GANZ RESTATED TRUST, ELINOR C. GANZ TRUSTEE

FIDELITY INVESTMENTS CUSTODIAN FOR ELINOR C. GANZ IRA ROLLOVER

FRANK CARLUCCI

GANZ FAMILY FOUNDATION

HTI VENTURES LLC ATTN ADI

JAMES DAVIDSON

JOHN S LEMAK

JONATHAN HONIG

LION BROTHERS

MEITAV GEMEL LTD. ON BEHALF OF BANK BENLEUMI

MEITAV GEMEL LTD. ON BEHALF OF BANK LEUMI

MEITAV INVESTMENT MANAGEMENT LTD.

MEITAV MISHAN LTD. ON BEHALF OF BANK HAPOALIM

MEITAV PENSION LTD

MEITAV UNDERWRITING LTD

MICHAEL & BETSY BRAUSER TENANTS BY ENTIRETY

MICHAEL & BETSY BRAUSER TENANTS BY ENTIRETY

MICHAEL G. JESSELSON 12/18/80 TRUST

MONARCH CAPITAL FUNDS LTD.

OPALLO INVESTMENT

PARADOX TRADING COMPANY LLC

PAUL CROITOROO

PEDDLE PARTNERS LLP

POINT INVESTMENTS

RACHELLE OSTRO HAIM OSTRO

ROBERT PRAG

ROBERT S. COLMAN TRUST U/D/T 3/13/85

RONALD I. HELLER REVOCABLE TRUST

RONALD I. HELLER REVOCABLE TRUST

SAMUEL BARTOLETTA

SANDOR CAPITAL MASTER FUND, L.P.

SCOTT FROHMAN

SHAI MERETZKI

SHIMON AND MORDECAHAI VOGEL

KINDER INVESTMENTS LP.

SHMUEL COHEN

SHOSHANA MERCHAV

 

 

 



 

 

 

SPRING CHARITABLE REMAINDER TRUST

SUSAN GANZ

TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD

THE WOOD RIVER FUND

TIFFANY PALAGONIA

WILLIAM R. PRATHER REVOCABLE TRUST

YAACOV & ANAT YANAY

ZVI EINTRACHT AND AYA EINTRACHT TENANTS IN COMMON WROS

 

 

 

 

 

 

 

ASSIGNMENT AGREEMENT

This Assignment Agreement (the " Agreement ") is entered into this 15th day of May 2007 (“ Effective Date ”), by and between Pluristem Life Systems, Inc., a Nevada corporation (" Pluristem ") and the_________________. (the " Technion " or the “ Assignor ”).

 

WITNESSETH :

WHEREAS ,

Pluristem, the Assignor and other licensors have entered into that certain Exclusive World-Wide Patent and Technology License and Assignment Agreement dated May 1, 2003 (the “ License Agreement ”) (Assignor was defined as “Licensor” under such License Agreement); and

WHEREAS ,

under the License Agreement, Pluristem was granted an exclusive worldwide license to exploit the " Patent " (as defined in the License Agreement) , as well as the " Intellectual Property " (as defined in the License Agreement) to make, have made, use, market and sell " Products " (as defined in the License Agreement) worldwide; and

WHEREAS,

under the License Agreement, Pluristem granted to the Assignor the " Option " (as defined in the License Agreement") to assign its rights in the Patent in exchange for the issuance of a certain percentage of the Common Stock of Pluristem (the " Stock "); and

WHEREAS ,

the Assignor has agreed to assign its rights in the Patent in exchange for the monetary consideration offered by Pluristem, in lieu of such share capital, as provided hereunder.

 

NOW THEREFORE , the parties hereby agree as follows:

 

1.

Definitions

All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement.

 

2.

Assignment

 

2.1

Subject to the receipt of the consideration in full, as set forth in Section 3 below (the " Consideration "), the Assignor hereby irrevocably sells, assigns, relinquishes, conveys and transfers to Pluristem any and all of the right, title, and interest that it may have in the Patent, Product, and the Intellectual Property, free and clear of any and all liens, charges or encumbrances and Pluristem hereby acquires and takes assignment and delivery of all and any right in the Patent and Intellectual Property (the “ Assignment ”). Appendix 1 attached hereto lists all of the patents and patent applications that constitute the "Patent". The Assignor shall execute the assignment deed attached hereto as Appendix 2 and deliver it to Pluristem against payment of the Consideration. Upon the occurrence of such cross-obligations, the assignment transaction envisaged hereunder shall be deemed as having been consummated (the " Closing ").

 

2.2

It is acknowledged and agreed that following the Assignment hereunder, as between the Assignor and Pluristem, any and all right, title and interest in and/or to the Patent, the Intellectual Property, the Products and/or any derivatives thereof, and the ownership of all of the above, shall be exclusively and undisputedly held by Pluristem.

 

2.3

For the avoidance of doubt, the License Agreement shall be deemed terminated as of the Closing, with the exception of those provisions which remain in force and effect pursuant to the provisions of this Agreement.

 

Page 1 of 8

Confidential

 



 

 

 

3.

Consideration

Notwithstanding the terms and conditions of the Option, the Assignor acknowledges that in lieu of the Stock to which it would have been entitled in consideration for the Assignment, as set forth in the License Agreement, Pluristem shall pay to the Assignor, as full and final consideration for the Assignment, the amount of US$ ________________ (US Dollar ________________________) (the “ Consideration ”) within 7 (seven) business days of the date hereof. The Consideration shall be wired to Assignor's bank accounts as set out in Appendix 3 , net of any set-offs, withholding taxes, banking charges or other deductions of any nature. Upon receipt of the Consideration in full, the Assignor shall be deemed as having waived its rights to exercise the Option. For the avoidance of doubt, the Technion shall be solely responsible for any and all entitlements of the researchers from its institutions in relation to the transaction contemplated herein.

 

4.

No Royalties

Subject to the Closing, the Assignor releases Pluristem from any obligation to pay to the Assignor any royalties, lump sum payments or other consideration received due to any sublicense granted by Pluristem (“ Royalties ”) under Section 4 of the License Agreement. The Assignor warrants and represents that as of the date hereof, it shall not raise any claim, allegation and/or assertion with respect to Royalties pursuant to Section 4 of the Agreement, or have any right to Royalties from Pluristem henceforth and/or as otherwise deemed by Assignor as due prior to or following the date hereof, including, without limitation, in connection with the Patent, the Intellectual Property, the Products and/or any derivatives thereof. Pluristem represents that until the date hereof, other than the sublicense with Stem Cells Innovations Inc. no other sublicense transactions were concluded.

 

5.

Representations and Warranties of the Assignor

 

5.1

The Technion represents and warrants that :

 

5.1.1

It has the right to assign its rights in the Patent and to consummate the transactions contemplated by this Agreement, and has not executed any agreement in conflict herewith; and

 

5.1.2

The Patent has not been sold, encumbered, assigned or licensed to any third party.

 

5.1.3

The Assignment shall not conflict with or constitute a breach of any contract or agreement to which the Assignor is a party.

 

5.1.4

It has not agreed or undertaken to pay any royalties or other payments to third parties with respect to the marketing, sale, distribution, manufacture, license or use of any right relating to the Patent, and there is no obligation on the part of Assignor to pay any such royalties or other payments in relation to the Patent.

 

5.2

To the best of the knowledge of the Technion, the Technion, together with Dr. Shoshana Merchav and Dr. Shay Meretzky, are the sole owners of all rights, title and interest in the Intellectual Property, and has not agreed or undertaken to pay any royalties or other payments to third parties with respect to the marketing, sale, distribution, manufacture, license or use of any right relating to the Intellectual Property.

 

5.3

THE ASSIGNOR MAKES NO WARRANTY OF PATENTABILITY, MERCHANTABILITY, COMMERCIAL VALUE OR FITNESS OF THE PATENT FOR A PARTICULAR PURPOSE. THE ASSIGNOR MAKES NO REPRESENTATION OR WARRANTY AND HEREBY DISCLAIMS ALL LIABILITY RELATED TO THE VALIDITY, PATENTABILITY OR THE NONINFRINGING NATURE OF THE PATENT.

 

Page 2 of 8

Confidential

 



 

 

 

5.4

The Technion has not received any demand or claim from a third party alleging any violation, infringement or misappropriation of any third party's rights by the Patent or the Intellectual Property and is not aware of any such demand or claim.

 

6.

Affirmative Covenants of the Assignor

 

6.1

The Assignor agrees that it shall, from time to time, upon reasonable request by Pluristem, execute and deliver such additional instruments, documents, conveyances, assignment or assurances as shall be necessary to confirm and render effective the Assignment.

 

6.2

Pluristem shall bear the expenses incurred by the Assignor with respect to the Assignment of the Patent under this Agreement and compliance with the provisions of Section 6.1 above.

 

7.

Survival

 

7.1

Notwithstanding the termination of the License Agreement:

 

7.1.1

Section 6 shall continue to be in force and effect, it being understood and agreed that the restriction on Merchav pursuant to Section 6.2, shall expire on April 30, 2008;

 

7.1.2

Sections 7.2, 8.2, third sentence of Section 9 and 10.1 through 10.4 shall continue to be in force and effect, mutatis mutandis ; and

 

7.1.3

Section 16.3 shall continue to be in force and effect.

 

7.2

Notwithstanding the termination of the License Agreement, the provisions of Section 13 shall continue to apply to " Confidential Information " (as defined therein) that has been disclosed by any party to another party. The obligation of confidentiality shall continue for a period of five years, as of the Closing.

 

8.

Mutual Representations and Warranties

Each of the parties hereby represents and warrants that it has full power and authority to consummate the transactions contemplated hereunder, and the consummation of the transaction contemplated hereunder and the performance of this Agreement do not violate the provisions of any applicable law. Both parties represent and warrant that the execution and delivery of this Agreement and the fulfillment of their obligations hereof (i) will not constitute a default under or conflict with any agreement or other instrument to which they are a party or by which they are bound and (ii) do not require the consent of any person or entity.

 

9.

Miscellaneous.

 

9.1

Headings used in this Agreement are for reference only and shall not be deemed a part of this Agreement.

 

9.2

This Agreement, including all the appendices thereto, constitutes the entire agreement between the parties with respect to its subject matter, and supersedes and cancels all prior agreements, understandings and arrangements, written or oral, between the parties hereto with respect to the subject matter hereof, provided however, that this Section shall not operate to exclude liability of any fraudulent misrepresentation.

 

9.3

This Agreement may be executed in counterparts with the same force and effect as if each of the signatories had executed the same instrument.

 

9.4

No amendment of this Agreement shall be effective unless it is in writing and signed by a duly authorized representative of each party; The failure of either party at any time to require the performance by the other party of any provision of this Agreement shall not affect in any way the right to require such performance at any later time, nor shall the waiver by either party of a

 

Page 3 of 8

Confidential

 



 

breach of any provision hereof be taken or held to be an implied waiver of that provision.

 

9.5

In the event any provision of this Agreement shall be determined to be unenforceable, because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the rights and obligations of the parties shall be construed and enforced as if the Agreement did not contain the particular provision(s) held to be unenforceable.

 

9.6

Any notice under this Agreement shall be in writing and sent by registered or certified mail, by hand delivery, express courier, by facsimile or by electronic mail, and shall be deemed to have been duly given for all purposes (i) when received, or ten (10) days after it is mailed by prepaid registered or certified mail; (ii) upon the transmittal thereof by facsimile, (iii) upon the manual delivery thereof, or (iv) upon receipt by the sender of a confirmation notice if sent through electronic mail, to the respective addressee or fax numbers set forth herein or to such other address of which notice as aforesaid is actually received.

 

 

to Pluristem at:

Matam Advanced Technology Park,

 

Bldg 20, Haifa 31905

 

Israel

 

Attention:

Mr. Yaky Yanay

 

Facsimile:

04-8501085

 

E:mail: yaky@pluristem.com

 

to Technion at:

________

 

___________

 

Attention:

-------

 

Facsimile:

---------

 

E:mail:

 

9.7

Any and all disputes concerning this Agreement governed by laws of the State of Israel, regardless of its conflict of laws rules. The courts of Tel Aviv, Israel shall have sole jurisdiction in any dispute arising out of this Agreement.

 

IN WITNESS THEREOF the parties hereto have executed this Agreement as of the date first above written.

 

 

________________________

Pluristem Life Systems, Inc.

 

________________________________

 

By: ________________________

Name: Zami Aberman, Yaky Yanay

Title: ___CEO_________ CFO__

By: ________________________

Name: _____________________

Title: ______________________

 

 

 

Page 4 of 8

Confidential

 



 

 

Appendix 1

 

Country

Earliest Priority

Filing Date

 

Application No./Publication No.

Patent No.

USA

(Provisional)

 

04-Feb-1999

 

60/118,789

 

PCT

 

04-Feb-1999

60/118,789

04-Feb-2000

 

US00/02688

WO 00/46349

 

USA

 

04-Feb-1999

60/118,789

04-Feb-2000

 

09/890,401

6,911,201

Japan

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2000-597409

JP2002535981T2

 

Canada

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2,360,664

 

Mexico

 

04-Feb-1999

60/118,789

04-Feb-2000

 

PA/a/2001/007820

 

Australia

 

04-Feb-1999

60/118,789

04-Feb-2000

 

34807/00

759719

South Africa

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2001/6483

2001/6483

Europe

 

04-Feb-1999

60/118,789

04-Feb-2000

 

00913340.6

EP 1147176

 

Republic of Korea, NP

04-Feb-1999

60/118,789

04-Feb-2000

 

2001-7009869

 

Israel

 

04-Feb-1999

60/118,789

04-Feb-2000

 

144629

 

China

 

04-Feb-1999

60/118,789

04-Feb-2000

 

00806007.X

CN1346403T

 

Russian Federation NP

04-Feb-1999

60/118,789

04-Feb-2000

 

2001124399

2249039

Brazil

 

04-Feb-1999

60/118,789

04-Feb-2000

 

PI0009403-0

 

New Zealand

 

04-Feb-1999

60/118,789

04-Feb-2000

 

513303

513303

India

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2001/01131

 

Hong Kong

 

04-Feb-2000

60/118,789

24-Oct-2002

 

02107728.2

 

 

 

Page 5 of 8

Confidential

 



 

 

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,654

US20050181504

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,623

US20050180985

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,635

US20050176143

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,625

US20050176137

 

 

 

Page 6 of 8

Confidential

 



 

 

Appendix 2

Assignment Deed

 

[to be signed and attached]

 

 

 

Page 7 of 8

Confidential

 



 

 

 

Appendix 3

 

Bank Account Details

 

 

Name: ________________________________

 

Bank:   ________________________________

 

Branch:               ________________________________

 

Account Number: ________________________

 

Swift:   ________________________________

 

 

Page 8 of 8

Confidential

 

 

 

ASSIGNMENT AGREEMENT

This Assignment Agreement (the " Agreement ") is entered into this 15th day of May 2007 (“ Effective Date ”), by and between Pluristem Life Systems, Inc., a Nevada corporation (" Pluristem ") and Yeda Research and Development Company Ltd. (" Yeda " or the “ Assignor ”).

 

WITNESSETH :

WHEREAS ,

Pluristem, the Assignor and other licensors have entered into that certain Exclusive World-Wide Patent and Technology License and Assignment Agreement dated May 1, 2003 (the “ License Agreement ”) (Assignor was defined as “Licensor” under such License Agreement); and

WHEREAS ,

under the License Agreement, Pluristem was granted an exclusive worldwide license to exploit the " Patent " (as defined in the License Agreement) , as well as the " Intellectual Property " (as defined in the License Agreement) to make, have made, use, market and sell " Products " (as defined in the License Agreement) worldwide; and

WHEREAS,

under the License Agreement, Pluristem granted to the Assignor the " Option " (as defined in the License Agreement") to assign its rights in the Patent in exchange for the issuance of a certain percentage of the Common Stock of Pluristem (the " Stock "); and

WHEREAS ,

the Assignor has agreed to assign its rights in the Patent in exchange for the monetary consideration offered by Pluristem, in lieu of such Stock or share capital, as provided hereunder.

 

NOW THEREFORE , the parties hereby agree as follows:

 

1.

Definitions

All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the License Agreement.

 

2.

Assignment

 

2.1

Subject to the receipt of the consideration in full, as set forth in Section 3 below (the " Consideration "), the Assignor hereby irrevocably sells, assigns, relinquishes, conveys and transfers to Pluristem any and all of the right, title, and interest that it may have in the Patent, Product, and the Intellectual Property, free and clear of any and all liens, charges or encumbrances and Pluristem hereby acquires and takes assignment and delivery of all and any right in the Patent and Intellectual Property (the “ Assignment ”). Appendix 1 attached hereto lists all of the patents and patent applications that constitute the "Patent". The Assignor shall execute the assignment deed attached hereto as Appendix 2 and deliver it to Pluristem against payment of the Consideration. Upon the occurrence of such cross-obligations, the assignment transaction envisaged hereunder shall be deemed as having been consummated (the " Closing ").

 

2.2

It is acknowledged and agreed that following the Assignment hereunder, as between the Assignor and Pluristem, any and all right, title and interest in and/or to the Patent, the Intellectual Property, the Products and/or any derivatives thereof, and the ownership of all of the above, shall be exclusively and undisputedly held by Pluristem.

 

2.3

For the avoidance of doubt, the License Agreement shall be deemed terminated as of the Closing, with the exception of those provisions which remain in force and effect pursuant to

 

Page 1 of 8

Confidential

 



 

the provisions of this Agreement.

 

2.4

Yeda hereby undertakes to execute and use its best efforts to cause Prof. Dov Zipori and Prof. Avinoam Kadouri to execute any and all instruments requested reasonably by Pluristem with respect to the Patent, as Pluristem shall deem fit in order to perfect the ownership of Pluristem in and to the Patent.

 

3.

Consideration

Notwithstanding the terms and conditions of the Option, the Assignor acknowledges that in lieu of the Stock to which it would have been entitled in consideration for the Assignment, as set forth in the License Agreement, Pluristem shall pay to the Assignor, as full and final consideration for the Assignment, the amount of US$ 490,625(US Dollar Four Hundred and Ninety Thousand and Six Hundred Twenty Five) (the “ Consideration ”) within 7 (seven) business days of the date hereof. The Consideration shall be wired to Assignor's bank accounts as set out in Appendix 3 , net of any set-offs, withholding taxes, banking charges or other deductions of any nature. Upon receipt of the Consideration in full, the Assignor shall be deemed as having waived its rights to exercise the Option. For the avoidance of doubt, Yeda shall be solely responsible for any and all entitlements of the researchers from its institutions in relation to the transaction contemplated herein.

 

4.

No Royalties

Subject to the Closing, the Assignor releases Pluristem from any obligation to pay to the Assignor any royalties, lump sum payments or other consideration received due to any sublicense granted by Pluristem (“ Royalties ”) under Section 4 of the License Agreement. The Assignor warrants and represents that as of the date hereof, it shall not raise any claim, allegation and/or assertion with respect to Royalties pursuant to Section 4 of the Agreement, or have any right to Royalties from Pluristem henceforth and/or as otherwise deemed by Assignor as due prior to or following the date hereof, including, without limitation, in connection with the Patent, the Intellectual Property, the Products and/or any derivatives thereof. Pluristem represents that until the date hereof, other than the sublicense with Stem Cells Innovations Inc. no other sublicense transactions were concluded.

 

5.

Representations and Warranties of the Assignor

 

5.1

Yeda represents and warrants that:

 

5.1.1

It has the right to assign its rights in the Patent and to consummate the transactions contemplated by this Agreement, and has not executed any agreement in conflict herewith; and

 

5.1.2

The Patent has not been sold, encumbered, assigned or licensed to any third party.

 

5.1.3

The Assignment shall not conflict with or constitute a breach of any contract or agreement to which the Assignor is a party.

 

5.1.4

It has not agreed or undertaken to pay any royalties or other payments to third parties with respect to the marketing, sale, distribution, manufacture, license or use of any right relating to the Patent, and there is no obligation on the part of Assignor to pay any such royalties or other payments in relation to the Patent other than the obligations that it may have vis-à-vis the Weizmann Institute of Science and its researchers and/or employees.

 

5.2

THE ASSIGNOR MAKES NO WARRANTY OF PATENTABILITY, MERCHANTABILITY, COMMERCIAL VALUE OR FITNESS OF THE PATENT FOR A PARTICULAR PURPOSE. THE ASSIGNOR MAKES NO REPRESENTATION OR WARRANTY AND HEREBY DISCLAIMS ALL LIABILITY

 

Page 2 of 8

Confidential

 



 

RELATED TO THE VALIDITY, PATENTABILITY OR THE NONINFRINGING NATURE OF THE PATENT.

 

5.3

Yeda is not aware of any demand or claim from a third party alleging any violation, infringement or misappropriation of any third party's rights by the Patent or the Intellectual Property having been received by the Technion Research and Development Foundation Ltd...

 

6.

Affirmative Covenants of the Assignor

 

6.1

The Assignor agrees that it shall, from time to time, upon reasonable request by Pluristem, execute and deliver such additional instruments, documents, conveyances, assignment or assurances as shall be necessary to confirm and render effective the Assignment.

 

6.2

Pluristem shall bear the expenses incurred by the Assignor with respect to the Assignment of the Patent under this Agreement and compliance with the provisions of Section 6.1 above.

 

7.

Survival

 

7.1

Notwithstanding the termination of the License Agreement:

 

7.1.1

Section 6 shall continue to be in force and effect, it being understood and agreed that the restriction on Merchav pursuant to Section 6.2, shall expire on April 30, 2008;

 

7.1.2

Sections 7.2, 8.2, third sentence of Section 9 and 10.1 through 10.4 shall continue to be in force and effect, mutatis mutandis ; and

 

7.1.3

Section 16.3 shall continue to be in force and effect.

 

7.2

Notwithstanding the termination of the License Agreement, the provisions of Section 13 shall continue to apply to " Confidential Information " (as defined therein) that has been disclosed by any party to another party. The obligation of confidentiality shall continue for a period of five years, as of the Closing.

 

8.

Mutual Representations and Warranties

Each of the parties hereby represents and warrants that it has full power and authority to consummate the transactions contemplated hereunder, and the consummation of the transaction contemplated hereunder and the performance of this Agreement do not violate the provisions of any applicable law. Both parties represent and warrant that the execution and delivery of this Agreement and the fulfillment of their obligations hereof (i) will not constitute a default under or conflict with any agreement or other instrument to which they are a party or by which they are bound and (ii) do not require the consent of any person or entity.

 

9.

Miscellaneous.

 

9.1

Headings used in this Agreement are for reference only and shall not be deemed a part of this Agreement.

 

9.2

This Agreement, including all the appendices thereto, constitutes the entire agreement between the parties with respect to its subject matter, and supersedes and cancels all prior agreements, understandings and arrangements, written or oral, between the parties hereto with respect to the subject matter hereof, provided however, that this Section shall not operate to exclude liability of any fraudulent misrepresentation.

 

9.3

This Agreement may be executed in counterparts with the same force and effect as if each of the signatories had executed the same instrument.

 

9.4

No amendment of this Agreement shall be effective unless it is in writing and signed by a duly

 

Page 3 of 8

Confidential

 



 

authorized representative of each party; The failure of either party at any time to require the performance by the other party of any provision of this Agreement shall not affect in any way the right to require such performance at any later time, nor shall the waiver by either party of a breach of any provision hereof be taken or held to be an implied waiver of that provision.

 

9.5

In the event any provision of this Agreement shall be determined to be unenforceable, because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the rights and obligations of the parties shall be construed and enforced as if the Agreement did not contain the particular provision(s) held to be unenforceable.

 

9.6

Any notice under this Agreement shall be in writing and sent by registered or certified mail, by hand delivery, express courier, by facsimile or by electronic mail, and shall be deemed to have been duly given for all purposes (i) when received, or ten (10) days after it is mailed by prepaid registered or certified mail; (ii) upon the transmittal thereof by facsimile, (iii) upon the manual delivery thereof, or (iv) upon receipt by the sender of a confirmation notice if sent through electronic mail, to the respective addressee or fax numbers set forth herein or to such other address of which notice as aforesaid is actually received.

 

 

to Pluristem at:

Matam Advanced Technology Park,

 

Bldg 20, Haifa 31905

 

Israel

 

Attention:

Mr. Yaky Yanay

 

Facsimile:

04-8501085

 

E:mail: yaky@pluristem.com

 

 

to Yeda at:

P.O. Box 95

 

Rehovot 76100

 

Attention:

the CEO

 

Facsimile:

(08) 9470739

 

E:mail:

 

9.7

Any and all disputes concerning this Agreement governed by laws of the State of Israel, regardless of its conflict of laws rules. The courts of Tel Aviv, Israel shall have sole jurisdiction in any dispute arising out of this Agreement.

 

IN WITNESS THEREOF the parties hereto have executed this Agreement as of the date first above written.

 

 


________________________

Pluristem Life Systems, Inc.

 

________________________________

Yeda Research and Development Company Ltd.

 

By: ________________________

Name: Zami Aberman, Yaky Yanay

Title: ___CEO_________ CFO__

By: ________________________

Name: _____________________

Title: ______________________

 

 

 

Page 4 of 8

Confidential

 



 

 

Appendix 1

 

Country

Earliest Priority

Filing Date

 

Application No./Publication No.

Patent No.

USA

(Provisional)

 

04-Feb-1999

 

60/118,789

 

PCT

 

04-Feb-1999

60/118,789

04-Feb-2000

 

US00/02688

WO 00/46349

 

USA

 

04-Feb-1999

60/118,789

04-Feb-2000

 

09/890,401

6,911,201

Japan

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2000-597409

JP2002535981T2

 

Canada

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2,360,664

 

Mexico

 

04-Feb-1999

60/118,789

04-Feb-2000

 

PA/a/2001/007820

 

Australia

 

04-Feb-1999

60/118,789

04-Feb-2000

 

34807/00

759719

South Africa

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2001/6483

2001/6483

Europe

 

04-Feb-1999

60/118,789

04-Feb-2000

 

00913340.6

EP 1147176

 

Republic of Korea, NP

04-Feb-1999

60/118,789

04-Feb-2000

 

2001-7009869

 

Israel

 

04-Feb-1999

60/118,789

04-Feb-2000

 

144629

 

China

 

04-Feb-1999

60/118,789

04-Feb-2000

 

00806007.X

CN1346403T

 

Russian Federation NP

04-Feb-1999

60/118,789

04-Feb-2000

 

2001124399

2249039

Brazil

 

04-Feb-1999

60/118,789

04-Feb-2000

 

PI0009403-0

 

New Zealand

 

04-Feb-1999

60/118,789

04-Feb-2000

 

513303

513303

India

 

04-Feb-1999

60/118,789

04-Feb-2000

 

2001/01131

 

Hong Kong

 

04-Feb-2000

60/118,789

24-Oct-2002

 

02107728.2

 

 

 

Page 5 of 8

Confidential

 



 

 

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,654

US20050181504

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,623

US20050180985

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,635

US20050176143

 

USA

(CIP)

04-Feb-1999

60/118,789

11-Apr-2005

 

11/102,625

US20050176137

 

 

 

Page 6 of 8

Confidential

 



 

 

Appendix 2

Assignment Deed

 

[to be signed and attached]

 

 

 

Page 7 of 8

Confidential

 



 

 

 

Appendix 3

 

Bank Account Details

 

 

Name: Yeda Research and Development

Company Ltd.

 

Bank:   Hapoalim B.M.

 

Branch: Rehovot Branch (No. 615)

 

Account Number: 37852

 

Swift:   POALILIT

ABA: 026008866

 

 

Page 8 of 8

Confidential

 

 

 

SUBSCRIPTION AGREEMENT

THIS SUBSCRIPTION AGREEMENT (this “ Agreement ”), dated as of May ____, 2007, by and among Pluristem Life Systems, Inc., a Nevada corporation (the “ Company ”), and the subscribers identified on the signature page hereto (each a “ Subscriber ” and collectively “ Subscribers ”).

WHEREAS , the Company and the Subscribers are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the provisions of Section 4(2), Section 4(6) and/or Regulation D (“ Regulation D ”) as promulgated by the United States Securities and Exchange Commission (the “ Commission ”) under the Securities Act of 1933, as amended (the “ 1933 Act ”).

WHEREAS , the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Subscribers, as provided herein, and the Subscribers, in the aggregate, shall purchase for a minimum of $7,000,000 and up to a maximum of $13,500,000 (the " Purchase Price ") shares of the Company's common stock, $.00001 par value (the " Common Stock ") at a per share price of $0.0125, and share purchase warrants (the “ Warrants ”) in the form attached hereto as Exhibit A , to purchase shares of Common Stock (the “ Warrant Shares ”). The shares of Common Stock (the “ Shares ”), the Warrants and the Warrant Shares are collectively referred to herein as the " Securities "; and

WHEREAS , the aggregate proceeds of the sale of the Shares and the Warrants contemplated hereby, and the other documents, instruments and payments contemplated hereby shall be delivered directly to the Company to the account described on Exhibit B hereto (the " Company Account ").

NOW, THEREFORE , in consideration of the mutual covenants and other agreements contained in this Agreement the Company and the Subscribers hereby agree as follows:

1.              Closing . Subject to the satisfaction or waiver of the terms and conditions of this Agreement, on the “ Closing Date ” (as defined in Section 2 below), each Subscriber shall purchase and the Company shall sell to each Subscriber the Shares and Warrants designated on the signature page hereto for the portion of the Purchase Price set forth on the signature page hereto. The consummation of the transactions contemplated herein shall take place at the offices of Grushko & Mittman, P.C., 551 Fifth Avenue, Suite 1601, New York, New York 10176, upon the satisfaction of all conditions to Closing set forth in this Agreement (“ Closing Date ”).

 

2.              Closing Condition. The Closing shall occur upon receipt by the Company of signed subscription agreements from the Subscribers, the Purchase Price deposited by the Subscribers with the Company pursuant to the wire instructions set forth on Exhibit B hereto, or, if pre-arranged by the Subscriber with the Company, by short term promissory note, and the Company accepting such Subscriptions. Upon such acceptance the Company will deliver to the Subscriber original certificates representing the Common Stock and Warrants purchased by the Subscribers pursuant to this Agreement and copies of all other signed agreements and documents reasonably requested by the Subscriber . If the payment was made by promissory note, the Company shall retain the certificates until the promissory note is fully paid.

 

3.              Warrants . On the Closing Date, the Company will issue and deliver Warrants to the Subscribers. One Warrant will be issued for each Share issued on the Closing Date. The per Warrant Share exercise price to acquire a Warrant Share upon exercise of a Warrant shall be $0.025. The Warrants shall be exercisable commencing upon the Closing Date and until five (5) years after the Closing Date.

 

 



 

 

4.              Subscriber's Representations and Warranties . Each Subscriber hereby represents and warrants to and agrees with the Company only as to such Subscriber that:

(a)             Information on Company . The Subscriber has been furnished with or has had access at the EDGAR Website of the Commission to the Company's Form 10-KSB for the year ended June 30, 2006 as filed with the Commission, together with all subsequently filed Forms 10-QSB, 8-K, and filings made with the Commission available at the EDGAR website (hereinafter referred to collectively as the " Reports "). In addition, the Subscriber has received in writing from the Company such other information concerning its operations, financial condition and other matters as the Subscriber has requested in writing (such other information is collectively, the " Other Written Information "), and considered all factors the Subscriber deems material in deciding on the advisability of investing in the Securities.

(b)             Information on Subscriber . The Subscriber is, and will be at the time of exercise of any of the Warrants, an " accredited investor ", as such term is defined in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United States publicly-owned companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable the Subscriber to utilize the information made available by the Company to evaluate the merits and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment. The Subscriber has the authority and is duly and legally qualified to purchase and own the Securities. The Subscriber is able to bear the risk of such investment for an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the Subscriber is accurate.

(c)             Purchase of Shares and Warrants . On the Closing Date, the Subscriber will purchase the Shares and Warrants as principal for its own account for investment only and not with a view toward, or for resale in connection with, the public sale or any distribution thereof.

(d)            Compliance with 1933 Act . The Subscriber understands and agrees that the Securities have not been registered under the 1933 Act or any applicable state securities laws, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based in part on the accuracy of the representations and warranties of Subscriber contained herein), and that such Securities must be held indefinitely unless a subsequent disposition is registered under the 1933 Act and any applicable state securities laws or is exempt from such registration. Each Subscriber acknowledges that the holding period of the Shares and Warrants for purposes of Rule 144 under the 1933 Act shall commence on the Closing Date notwithstanding the date of delivery of Purchase Price by the Subscriber to the Company except as set forth on Schedule 12 .

(e)             Shares and Warrant Shares Legend . The Shares and Warrant Shares shall bear the following or similar legend:

"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY

 

2

 



 

SATISFACTORY TO PLURISTEM LIFE SYSTEMS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED."

 

 

(f)

Warrants Legend . The Warrants shall bear the following

or similar legend:

"THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT OR ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO PLURISTEM LIFE SYSTEMS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED."

 

(g)            Communication of Offer . The offer to sell the Securities was directly communicated to the Subscriber by the Company. At no time was the Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form of general advertising or solicited or invited to attend a promotional meeting otherwise than in connection and concurrently with such communicated offer.

(h)            Authority; Enforceability . This Agreement and other agreements delivered together with this Agreement or in connection herewith have been duly authorized, executed and delivered by the Subscriber and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity; and Subscriber (if an entity) has full corporate power and authority necessary to enter into this Agreement and such other agreements and to perform its obligations hereunder and under all other agreements entered into by the Subscriber relating hereto.

 

(i)             Restricted Securities . Subscriber understands that the Securities have not been registered under the 1933 Act and such Subscriber will not sell, offer to sell, assign, pledge, hypothecate or otherwise transfer any of the Securities unless (i) pursuant to an effective registration statement under the 1933 Act, (ii) such Subscriber provides the Company with an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that a sale, assignment or transfer of the Securities may be made without registration under the 1933 Act, or (iii) Subscriber provides the Company with reasonable assurances (in the form of seller and broker representation letters) that the Warrant Shares may be sold pursuant to (A) Rule 144 promulgated under the 1933 Act, or (B) Rule 144(k) promulgated under the 1933 Act, in each case following the applicable holding period set forth therein. Notwithstanding anything to the contrary contained in this Agreement, such Subscriber may transfer (without restriction and without the need for an opinion of counsel) the Securities to its Affiliates (as defined below) and such Affiliate agrees to be bound by the terms and conditions of this Agreement. For the purposes of this Agreement, an “ Affiliate ” of any person or entity means any other person or entity directly or indirectly controlling, controlled by or under direct or indirect common control with such person

 

3

 



 

or entity. For purposes of this definition, “ control ” means the power to direct the management and policies of such person or firm, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise.

 

(j)             No Governmental Review . Each Subscriber understands that no United States federal or state agency or any other governmental or state agency has passed on or made recommendations or endorsement of the Securities or the suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(k)            Correctness of Representations . Each Subscriber represents as to such Subscriber that the foregoing representations and warranties are true and correct as of the date hereof and, unless a Subscriber otherwise notifies the Company prior to the Closing Date, shall be true and correct as of the Closing Date.

 

(l)              Survival . The foregoing representations and warranties shall survive the Closing Date for a period of four years.

5.              Company Representations and Warranties . Except as set forth in the Reports, the Company represents and warrants to and agrees with each Subscriber that:

(a)             Due Incorporation . The Company and each of its subsidiaries is a corporation duly organized, validly existing and in good standing under the laws of the respective jurisdictions of their incorporation and have the requisite corporate power to own their properties and to carry on their business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a Material Adverse Effect. For purpose of this Agreement, a “ Material Adverse Effect ” shall mean a material adverse effect on the financial condition, results of operations, properties or business of the Company taken as a whole. For purposes of this Agreement, “ Subsidiary ” means, with respect to any entity at any date, any corporation, limited or general partnership, limited liability company, trust, estate, association, joint venture or other business entity of which more than 50% of (i) the outstanding capital stock having (in the absence of contingencies) ordinary voting power to elect a majority of the board of directors or other managing body of such entity, (ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through one or more intermediaries, by such entity. As of the Closing Date, the Company’s only Subsidiary is Pluristem Ltd., a State of Israel corporation.

(b)            Outstanding Stock . All issued and outstanding shares of capital stock of the Company and each of its subsidiaries have been duly authorized and validly issued and are fully paid and nonassessable

(c)             Authority; Enforceability . This Agreement, the Shares, the Warrants, and any other agreements delivered together with this Agreement or in connection herewith (collectively “ Transaction Documents ”) have been duly authorized, executed and delivered by the Company and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors' rights generally and to general principles of equity. The Company has full

 

4

 



 

corporate power and authority necessary to enter into and deliver the Transaction Documents and to perform its obligations thereunder.

(d)            Additional Issuances . There are no outstanding agreements or preemptive or similar rights affecting the Company's common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or other equity interest in any of the subsidiaries of the Company except as described on Schedule 5(d) .

(e)             Consents . No consent, approval, authorization or order of any court, governmental agency or body or arbitrator having jurisdiction over the Company, or any of its Affiliates, the OTC Bulletin Board (the “ Bulletin Board ”) nor the Company's shareholders is required for the execution by the Company of the Transaction Documents and compliance and performance by the Company of its obligations under the Transaction Documents, including, without limitation, the issuance and sale of the Securities. The Transaction Documents and the Company’s performance of its obligations thereunder have been approved by the Company’s directors.

(f)             No Violation or Conflict . Assuming the representations and warranties of the Subscribers in Section 4 are true and correct, neither the issuance and sale of the Securities nor the performance of the Company’s obligations under this Agreement and all other agreements entered into by the Company relating thereto by the Company will:

(i)              violate, conflict with, result in a breach of, or constitute a default (or an event which with the giving of notice or the lapse of time or both would be reasonably likely to constitute a default) under (A) the certificate of incorporation, or bylaws of the Company, (B) to the Company's knowledge, any decree, judgment, order, law, treaty, rule, regulation or determination applicable to the Company of any court, governmental agency or body, or arbitrator having jurisdiction over the Company or any of its subsidiaries or over the properties or assets of the Company or any of its Affiliates, (C) the terms of any bond, debenture, note or any other evidence of indebtedness, or any agreement, stock option or other similar plan, indenture, lease, mortgage, deed of trust or other instrument to which the Company or any of its Affiliates or subsidiaries is a party, by which the Company or any of its Affiliates or subsidiaries is bound, or to which any of the properties of the Company or any of its Affiliates or subsidiaries is subject, or (D) the terms of any "lock-up" or similar provision of any underwriting or similar agreement to which the Company, or any of its Affiliates or subsidiaries is a party except the violation, conflict, breach, or default of which would not have a Material Adverse Effect on the Company; or

(ii)            result in the creation or imposition of any lien, charge or encumbrance upon the Securities or any of the assets of the Company, its subsidiaries or any of its Affiliates; or

(iii)           result in the activation of any anti-dilution rights or a reset or repricing of any debt or security instrument of any other creditor or equity holder of the Company, nor result in the acceleration of the due date of any obligation of the Company; or

(iv)          result in the activation of any piggy-back registration rights of any person or entity holding securities of the Company or having the right to receive securities of the Company.

 

(g)

The Securities . The Securities upon issuance:

 

 

5

 



 

 

(i)             are, or will be, free and clear of any security interests, liens, claims or other encumbrances, subject to restrictions upon transfer under the 1933 Act and any applicable state securities laws;

 

(ii)            have been, or will be, duly and validly authorized and on the date of exercise of the Warrants and issuance of the Shares and Warrant Shares will be duly and validly issued, fully paid and nonassessable and, if registered pursuant to the 1933 Act, and resold pursuant to an effective registration statement will be free trading and unrestricted except for prospectus delivery requirements by the seller;

(iii)           will not have been issued or sold in violation of any preemptive or other similar rights of the holders of any securities of the Company;

(iv)           will not subject the holders thereof to personal liability by reason of being such holders; and

(v)           assuming the representations warranties of the Subscribers as set forth in Section 4 hereof are true and correct, will not result in a violation of Section 5 under the 1933 Act.

(h)            Litigation . There is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its Affiliates that would affect the execution by the Company or the performance by the Company of its obligations under the Transaction Documents. Except as disclosed in the Reports, there is no pending or, to the best knowledge of the Company, basis for or threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its Affiliates which litigation if adversely determined would have a Material Adverse Effect on the Company.

(i)             Reporting Company . The Company is a publicly-held company subject to reporting obligations pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the " 1934 Act ") and has a class of common equity registered pursuant to Section 12(g) of the 1934 Act. Pursuant to the provisions of the 1934 Act, the Company has timely filed all reports and other materials required to be filed thereunder with the Commission during the preceding twelve months.

(j)             No Market Manipulation . The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might reasonably be expected to, cause or result in stabilization or manipulation of the price of the Common Stock of the Company to facilitate the sale or resale of the Securities or affect the price at which the Securities may be issued or resold.

(k)             Information Concerning Company . The Reports contain all material information relating to the Company and its operations and financial condition as of their respective dates which information is required to be disclosed therein. Since the date of the financial statements included in the Reports, and except as modified in the Other Written Information or in the Schedules hereto, there has been no material adverse change in the Company's business, financial condition or affairs not disclosed in the Reports. The Reports do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances when made.

(l)              Stop Transfer . The Securities, when issued, will be restricted securities. The Company will not issue any stop transfer order or other order impeding the sale, resale or delivery of any of the Securities, except as may be required by any applicable federal or state securities laws or unless

 

6

 



 

the Securities are not paid in full and unless contemporaneous notice of such instruction is given to the Subscriber.

(m)           Defaults . The Company is not in violation of its certificate of incorporation or bylaws. Except as disclosed on Schedule 5(m) , the Company is (i) not in default under or in violation of any other material agreement or instrument to which it is a party or by which it or any of its properties are bound or affected, which default or violation would have a Material Adverse Effect on the Company, (ii) not in default with respect to any order of any court, arbitrator or governmental body or subject to or party to any order of any court or governmental authority arising out of any action, suit or proceeding under any statute or other law respecting antitrust, monopoly, restraint of trade, unfair competition or similar matters, or (iii) to its knowledge, not in violation of any statute, rule or regulation of any governmental authority which violation would have a Material Adverse Effect on the Company.

(n)            Not an Integrated Offering. Neither the Company, nor any of its Affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offer of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of the Bulletin Board. Nor will the Company or any of its Affiliates or subsidiaries take any action or steps that would cause the offer or issuance of the Securities to be integrated with other offerings. Other than issuance of warrants to parties connected to the offer of the Securities, the Company will not conduct any offering other than the transactions contemplated hereby that will be integrated with the offer or issuance of the Securities.

(o)            No General Solicitation . Neither the Company, nor any of its Affiliates, nor to its knowledge, any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection with the offer or sale of the Securities.

(p)            Listing . The Company's common stock is quoted on the Bulletin Board. The Company has not received any oral or written notice that its common stock is not eligible nor will become ineligible for quotation on the Bulletin Board nor that its common stock does not meet all requirements for the continuation of such quotation. The Company satisfies all the requirements for the continued quotation of its common stock on the Bulletin Board.

(q)            No Undisclosed Liabilities . The Company has no liabilities or obligations which are material, individually or in the aggregate, which are not disclosed in the Reports and Other Written Information, other than those incurred in the ordinary course of the Company’s businesses since June 30, 2006 and which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect except as set forth in Schedule 5(m) .

(r)             No Undisclosed Events or Circumstances . Since June 30, 2006, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which has not been so publicly announced or disclosed in the Reports.

(s)             Capitalization . The authorized and outstanding capital stock of the Company as of the date of this Agreement and the Closing Date are set forth on Schedule 5(d) . Except as set forth on Schedule 5(d) and in the Company’s Reports, there are no options, warrants, or rights to subscribe to, securities, rights or obligations convertible into or exchangeable for or giving any right to

 

7

 



 

subscribe for any shares of capital stock of the Company. All of the outstanding shares of Common Stock of the Company have been duly and validly authorized and issued and are fully paid and nonassessable.

(t)             Dilution . The Company's executive officers and directors understand the nature of the Securities being sold hereby and recognize that the issuance of the Securities will have a potential dilutive effect on the equity holdings of other holders of the Company’s equity or rights to receive equity of the Company. The board of directors of the Company has concluded, in its good faith business judgment, that the issuance of the Securities is in the best interests of the Company. The Company specifically acknowledges that its obligation to issue the Warrant Shares upon exercise of the Warrants is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other shareholders of the Company or parties entitled to receive equity of the Company.

(u)            No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company.

 

(v)            DTC Status . The Company’s transfer agent is a participant in and the Common Stock is eligible for transfer pursuant to the Depository Trust Company Automated Securities Transfer Program. The name, address, telephone number, fax number, contact person and email address of the Company transfer agent is set forth on Schedule 5(v) hereto.

 

(w)            Investment Company . Neither the Company nor any Affiliate is an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

(x)             Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

(y)             Solvency . Based on the financial condition of the Company as of the Closing Date after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature; (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).

 

(z)             Subsidiary Representations . The Company makes each of the representations contained in Sections 5(a), (b), (d), (f), (h), (k), (m), (q), (r), (s), (u), (w), (x) and (y) of this Agreement, as same relate to each Subsidiary of the Company.

 

8

 



 

 

(AA)        Correctness of Representations . The Company represents that the foregoing representations and warranties are true and correct as of the date hereof in all material respects, and, unless the Company otherwise notifies the Subscribers prior to the Closing Date, shall be true and correct in all material respects as of the Closing Date.

(BB)         Survival . The foregoing representations and warranties shall survive the Closing Date for a period of four years.

6.              Regulation D Offering . The offer and issuance of the Securities to the Subscribers is being made pursuant to the exemption from the registration provisions of the 1933 Act afforded by Section 4(2) of the 1933 Act and/or Rule 506 of Regulation D promulgated thereunder. On the Closing Date, the Company will provide an opinion reasonably acceptable to Subscriber from the Company's legal counsel opining on the availability of an exemption from registration under the 1933 Act as it relates to the offer and issuance of the Securities and other matters reasonably requested by Subscribers. A form of the legal opinion is annexed hereto as Exhibit C . The Company will provide, at the Company's expense, such other legal opinions in the future as are reasonably necessary for the issuance and resale of the Shares and Warrant Shares.

 

7.

Covenants of the Company .

 

7.1.

Covenants . The Company covenants and agrees with the Subscribers as follows:

(a)             Stop Orders . The Company will advise the Subscribers, promptly after it receives notice of issuance by the Commission, any state securities commission or any other regulatory authority of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose.

(b)            Listing/Quotation . . For so long as a Subscriber owns Warrants, the Company will maintain the quotation or listing of its Common Stock on the American Stock Exchange, Nasdaq SmallCap Market, Nasdaq National Market System, Bulletin Board, or New York Stock Exchange (whichever of the foregoing is at the time the principal trading exchange or market for the Common Stock (the “ Principal Market ”)), and will comply in all respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Principal Market, as applicable. For so long as a Subscriber owns Warrants, the Company will provide the Subscribers copies of all notices it receives notifying the Company of the actual delisting of the Common Stock from any Principal Market. As of the date of this Agreement and the Closing Date, the Bulletin Board is and will be the Principal Market.

(c)             Market Regulations . The Company shall notify the Commission, the Principal Market and applicable state authorities, in accordance with their requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation, for the legal and valid issuance of the Securities to the Subscribers and promptly provide copies thereof to Subscriber.

(d)            Reporting Requirements . From the date of this Agreement and until the sooner of (i) five (5) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers or (iii) the date the Subscribers are eligible to sell their Shares issued on Closing pursuant to Rule 144, without regard to volume limitations (the “ Outstanding Period ”), the Company will (v) cause the Common Stock to continue to be registered under Section 12(b) or 12(g) of the 1934 Act, (x) comply in all material respects with its reporting and filing obligations under the 1934 Act, (y) comply , in all material respects, with all reporting requirements that are applicable to an issuer

 

9

 



 

with a class of shares registered pursuant to Section 12(b) or 12(g) of the 1934 Act, as applicable, and (z) comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company will use its best efforts not to take any action or file any document (whether or not permitted by the 1933 Act or the 1934 Act or the rules thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said acts until the end of the Outstanding Period. During the Outstanding Period, the Company will use its best efforts to continue the listing or quotation of the Common Stock on the Principal Market or other market with the reasonable consent of Subscribers holding a majority of each of the Shares, Warrants and Warrant Shares, and will comply in all material respects with the Company's reporting, filing and other obligations under the bylaws or rules of the Principal Market. The Company agrees to timely file a Form D with respect to the Securities if required under Regulation D and to provide a copy thereof to each Subscriber promptly after such filing.

(e)             Use of Proceeds . The proceeds of the Offering will be employed by the Company for working capital, investment activity, research and development.

 

(f)              Reservation . After increase of its authorized capital, which will occur after the Closing Date, the Company undertakes to reserve, pro rata , on behalf of each Subscriber, from its authorized but unissued common stock, a number of common shares equal to the amount of Warrant Shares issuable upon exercise of the Warrants. Failure to have sufficient shares reserved pursuant to this Section 7.1(f) for three (3) consecutive business days or ten (10) days in the aggregate shall be a material default of the Company’s obligations under this Agreement. The Subscriber acknowledges that currently the Company does not have sufficient authorized capital to reserve or issue all the Securities if the Offering is subscribed in full. The Company agrees to increase its authorized capital as soon as reasonably expedient after Closing.

(g)             Taxes . During the Outstanding Period, the Company will promptly pay and discharge, or cause to be paid and discharged, when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business of the Company; provided, however, that any such tax, assessment, charge or levy need not be paid if the validity thereof shall currently be contested in good faith by appropriate proceedings and if the Company shall have set aside on its books adequate reserves with respect thereto; and , provided, further, that the Company will pay all such taxes, assessments, charges or levies forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefor.

(h)             Insurance . During the Outstanding Period, the Company will keep its assets which are of an insurable character insured by financially sound and reputable insurers against loss or damage by fire, explosion and other risks customarily insured against by companies in the Company’s line of business, in amounts sufficient to prevent the Company from becoming a co-insurer at a reasonable percentage of the insurable value of the property insured; and the Company will maintain, with financially sound and reputable insurers, insurance against other hazards and risks and liability to persons and property to the extent and in the manner customary for companies in similar businesses similarly situated and to the extent available on commercially reasonable terms.

(i)             Books and Records. During the Outstanding Period, the Company will keep true records and books of account in which full, true and correct entries will be made of all dealings or transactions in relation to its business and affairs in accordance with generally accepted accounting principles applied on a consistent basis.

 

10

 



 

 

(j)             Governmental Authorities. During the Outstanding Period, the Company shall duly observe and conform in all material respects to all valid requirements of governmental authorities relating to the conduct of its business or to its properties or assets.

(k)             Intellectual Property . During the Outstanding Period, the Company shall maintain in full force and effect its corporate existence, rights and franchises and all licenses and other rights to use intellectual property owned or possessed by it and reasonably deemed by management to be necessary to the conduct of its business.

(l)              Properties. During the Outstanding Period, the Company will keep its properties in good repair, working order and condition, reasonable wear and tear excepted, and from time to time make all necessary and proper repairs, renewals, replacements, additions and improvements thereto; and the Company will at all times comply with each provision of all leases to which it is a party or under which it occupies property if the breach of such provision could reasonably be expected to have a Material Adverse Effect.

(m)           Confidentiality/Public Announcement. During the Outstanding Period, the Company agrees that except in connection with a Form 8-K or a registration statement or in correspondence with the SEC, the Company will not disclose publicly or privately the identity of the Subscribers unless expressly agreed to in writing by a Subscriber or only to the extent required by law and then only upon five days prior notice to Subscriber. In any event and subject to the foregoing, the Company undertakes to file a Form 8-K or make a public announcement describing the Offering not later than the fourth business day after the Closing Date. In the Form 8-K or public announcement, the Company will specifically disclose the amount of common stock outstanding immediately after the Closing.

(n)           Non-Public Information . The Company covenants and agrees that neither it nor any other Person acting on its behalf will provide any Subscriber or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Subscriber shall have agreed in writing to receive such information. The Company understands and confirms that each Subscriber shall be relying on the foregoing representations in effecting transactions in securities of the Company.

 

7.2.           Injunction - Posting of Bond . In the event a Subscriber shall elect to exercise the Warrant in whole or in part, the Company may not refuse exercise based on any claim that such Subscriber or any one associated or affiliated with such Subscriber has been engaged in any violation of law, or for any other reason, unless, an injunction from a court, on notice, restraining and or enjoining exercise of all or part of said Warrant shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit of such Subscriber in the amount of 130% of the aggregate purchase price of the Warrant Shares which are subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Subscriber to the extent Subscriber obtains judgment.

 

7.3.         Buy-In . In addition to any other rights available to the Subscriber, if the Company fails to deliver to the Subscriber such shares issuable upon exercise of a Warrant on or before the Delivery Date (as defined in the Warrant) and if seven (7) business days after the Delivery Date the Subscriber purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Subscriber of the Common Stock which the Subscriber was entitled to receive upon such exercise (a " Buy-In "), then the Company shall pay in cash to the Subscriber (in addition to any remedies available to or elected by the Subscriber) the amount by which (A) the Subscriber's total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (B) the

 

11

 



 

aggregate exercise price for which such exercise was not timely honored, together with interest thereon at a rate of 15% per annum, accruing until such amount and any accrued interest thereon is paid in full (which amount shall be paid as liquidated damages and not as a penalty). For example, if the Subscriber purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of $10,000 of Warrant exercise price, the Company shall be required to pay the Subscriber $1,000, plus interest, less any excess obtained from sale of the Warrants. The Subscriber shall provide the Company written notice and evidence indicating the amounts payable to the Subscriber in respect of the Buy-In.

 

 

7.4.

DELETED

 

7.5.           Negative Covenants . During the Outstanding Period , without the consent of the Subscriber, the Company will not and will not permit any of its Subsidiaries to directly or indirectly:

 

(i)              create, incur, assume or suffer to exist any pledge, hypothecation, assignment, deposit arrangement, lien, charge, claim, security interest, security title, mortgage, security deed or deed of trust, easement or encumbrance, or preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever (including any lease or title retention agreement, any financing lease having substantially the same economic effect as any of the foregoing, and the filing of, or agreement to give, any financing statement perfecting a security interest under the Uniform Commercial Code or comparable law of any jurisdiction) (each, a “ Lien ”) upon any of its property, whether now owned or hereafter acquired except for: (i) the Excepted Issuances (as defined in Section 7.4 hereof), and (ii) (a) Liens imposed by law for taxes that are not yet due or are being contested in good faith and for which adequate reserves have been established in accordance with generally accepted accounting principles; (b) carriers’, warehousemen’s, mechanics’, material men’s, repairmen’s and other like Liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than 30 days or that are being contested in good faith and by appropriate proceedings; (c) pledges and deposits made in the ordinary course of business in compliance with workers’ compensation, unemployment insurance and other social security laws or regulations; (d) deposits to secure the performance of bids, trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; (e) Liens created with respect to the financing of the purchase of new property in the ordinary course of the Company’s business up to the amount of the purchase price of such property; or (f) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business that do not secure any monetary obligations and do not materially detract from the value of the affected property (each of (a) through (f), a “ Permitted Lien ”);

 

(ii)           amend its certificate of incorporation, bylaws or its charter documents so as to adversely affect any rights of the Subscriber;

 

(iii)           repay, repurchase or offer to repay, repurchase or otherwise acquire or make any dividend or distribution in respect of any of its Common Stock, preferred stock, or other equity securities other than to the extent permitted or required under the Transaction Documents;

 

(iv)          engage in any transactions with any officer, director, employee or any Affiliate of the Company, including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $25,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company, (iii) director or advisory board

 

12

 



 

fees, and (iv) for other employee benefits, including stock option agreements under any stock option plan of the Company; or

 

(v)           prepay or redeem any financing related debt outstanding as of the Closing Date.

 

7.6           Offering Restrictions . Until four years after the Closing Date (“ Restriction Period ”) and except for the Excepted Issuances (defined below), the Company will not enter into an agreement to nor issue any equity, options, warrants, rights, convertible debt or other securities convertible into or exchangeable for Common Stock or other equity of the Company at an effective price of less than $0.0125 per share of Common Stock, nor modify any of the foregoing which may be outstanding during the Restriction Period if the effect of such modification would be to reduce to effective price of such Common Stock to less than $0.0125 per share without the prior written consent of each Subscriber holding a Securities at the time of such issuance, which consent may be withheld for any reason. The foregoing restriction shall not apply after a period of 180 days occurring entirely later than two years after the Closing Date during which the Common Stock has an average closing price as reported by Bloomberg LP for the Principal Market of not less than $0.05. “ Excepted Issuances ” shall mean (i) full or partial consideration in connection with a strategic merger, acquisition, consolidation or purchase of substantially all or a portion of the securities or assets of corporation or other entity which holders of such securities or debt are not at any time granted registration rights, (ii) the Company’s issuance of securities in connection with strategic license agreements and other partnering arrangements so long as such issuances are not for the purpose of raising capital and which holders of such securities or debt are not at any time granted registration rights, (iii) the Company’s issuance of Common Stock or the issuances or grants of options to purchase Common Stock pursuant to stock option plans and employee stock purchase plans described in the Reports, and (iv) as a result of the exercise of Warrants or the conversion or exchange of instruments which are granted or issued pursuant to this Agreement or that have been issued prior to the Closing Date all on the original terms thereof, the issuance of which has been disclosed in a Report filed not less than five (5) days prior to the Closing Date

 

8.             Finder. The Company on the one hand, and each Subscriber (for itself only) on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any persons claiming brokerage commissions or finder’s fees on account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby and arising out of such party’s actions. The Company represents that there are may be one or more parties entitled to receive fees, commissions, or similar payments in connection with the Offering , with such fees, commissions or payments being the responsibility of the Company.

9.              Legal Fees . On the Closing Date, the Company shall pay to Grushko & Mittman, P.C., a fee of $25,000 (“ Legal Fees ”) as reimbursement for services rendered to the Subscribers in connection with this Agreement and the purchase and sale of the Shares and Warrants (the “ Offering ”). The obligation for the payment of the fees will be applicable only if Grushko & Mittman, P.C has actually represented the Subscribers.

 

10.

Covenants of the Company and Subscriber Regarding Indemnification.

(a)             The Company agrees to indemnify, hold harmless, reimburse and defend the Subscribers, the Subscribers' officers, directors, agents, Affiliates, control persons, and principal shareholders, against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Subscriber or any such person which results, arises out of or is based upon (i) any material misrepresentation by Company or breach of any warranty by

 

13

 



 

Company in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed by the Company hereunder, or any other agreement entered into by the Company and Subscriber relating hereto.

(b)            Each Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, Affiliates, control persons against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Company or any such person which results, arises out of or is based upon (i) any material misrepresentation by such Subscriber in this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by such Subscriber of any covenant or undertaking to be performed by such Subscriber hereunder, or any other agreement entered into by the Company and Subscribers, relating hereto.

(c)             In no event shall the liability of any Subscriber or permitted successor hereunder or under any other agreement delivered in connection herewith be greater in amount than the dollar amount of the net proceeds actually received by such Subscriber upon the sale of Registrable Securities (as defined herein).

(d)          The procedures set forth in Section 11.6 shall apply to the indemnification set forth in Sections 10(a) and 10(b) above.

11.1.         Piggyback Registration Rights . The Company hereby grants the following registration rights to holders of the Securities. If the Company at any time during the Outstanding Period proposes to register any of its securities under the 1933 Act for sale to the public, whether for its own account or for the account of other security holders or both, except with respect to registration statements on Forms S-4, S-8 or another form not available for registering the Shares and Warrant Shares (collectively, the “ Registrable Securities ”) for sale to the public, provided the Registrable Securities are not otherwise registered for resale by the Subscribers or Holder pursuant to an effective registration statement, each such time it will give at least fifteen (15) days' prior written notice to the record holder of the Registrable Securities of its intention so to do. Upon the written request of the holder, received by the Company within ten (10) days after the giving of any such notice by the Company, to register any of the Registrable Securities not previously registered, the Company will cause such Registrable Securities as to which registration shall have been so requested to be included with the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent required to permit the sale or other disposition of the Registrable Securities so registered by the holder of such Registrable Securities (the “ Seller ” or “ Sellers ”). Unless instructed in writing to the contrary, the Subscribers hereby automatically exercise the registration rights granted in this Section 11.1. The Seller is hereby given the same rights and benefits as any other party identified in such registration. In the event that any registration pursuant to this Section 11.1 shall be, in whole or in part, an underwritten public offering of common stock of the Company, the number of shares of Registrable Securities to be included in such an underwriting may be reduced by the managing underwriter if and to the extent that the Company and the underwriter shall reasonably be of the opinion that such inclusion would adversely affect the marketing of the securities to be sold by the Company therein; provided, however, that the Company shall notify the Seller in writing of any such reduction. Notwithstanding the foregoing provisions, or Section 11.4 hereof, the Company may withdraw or delay or suffer a delay of any registration statement referred to in this Section 11.1 without thereby incurring any liability to the Seller due to such withdrawal or delay. The registration rights granted herein do not apply to the post-effective amendment being registered regarding the April 3, 2006 financing. In addition, in the event the Company raises funds by way of private placement and is contractually required to register the securities issued in the private placement, in the event the number of

 

14

 



 

securities to be registered is restricted under SEC rules or securities law requirements, the securities in the private placement will have priority over the Warrants and only those number of Warrants which may be registered without breaching Rule 415 or other applicable SEC rules will be registered with the private placement registration statement.

11.2.         Registration Procedures . If and whenever the Company is required by the provisions of Section 11.1 to effect the registration of any Registrable Securities under the 1933 Act, the Company will, as expeditiously as possible:

(a)             subject to the timelines provided in this Agreement, prepare and file with the Commission a registration statement required by Section 11, with respect to the Registrable Securities and use its best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby (determined as herein provided), and promptly provide to the holders of the Registrable Securities copies of all filings and Commission letters of comment and notify Subscribers and Grushko & Mittman, P.C. (by telecopier and by email to Counslers@aol.com ) within three (3) business days of (i) notice that the Commission has no comments or no further comments on the Registration Statement, and (ii) the declaration of effectiveness of the registration statement;

(b)             furnish to the Sellers, at the Company’s expense, such number of copies of the registration statement and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or their disposition of the securities covered by such registration statement;

 

(d)            if applicable, list the Registrable Securities covered by such registration statement with any securities exchange on which the Common Stock of the Company is then listed;

(e)             immediately notify the Sellers when a prospectus relating thereto is required to be delivered under the 1933 Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and

(f)             provided same would not be in violation of the provision of Regulation FD under the 1934 Act, make available for inspection by the Sellers, and any attorney, accountant or other agent retained by the Seller or underwriter, all publicly available, non-confidential financial and other records, pertinent corporate documents and properties of the Company, and cause the Company's officers, directors and employees to supply all publicly available, non-confidential information reasonably requested by the seller, attorney, accountant or agent in connection with such registration statement.

11.3.         Provision of Documents . In connection with each registration described in this Section 11, each Seller will furnish to the Company in writing such information and representation letters with respect to itself and the proposed distribution by it as reasonably shall be necessary in order to assure compliance with federal and applicable state securities laws.

 

11.4.

RESERVED

11.5.         Expenses . All expenses incurred by the Company in complying with Section 11, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including reasonable counsel fees) incurred in connection with complying with state securities or “blue sky” laws, fees of the

 

15

 



 

National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of insurance and fee of one counsel for all Sellers are called “ Registration Expenses .” All underwriting discounts and selling commissions applicable to the sale of Registrable Securities, including any fees and disbursements of any additional counsel to the Seller, are called " Selling Expenses ." The Company will pay all Registration Expenses in connection with the registration statement under Section 11. Selling Expenses in connection with each registration statement under Section 11 shall be borne by the Seller and may be apportioned among the Sellers in proportion to the number of shares sold by the Seller relative to the number of shares sold under such registration statement or as all Sellers thereunder may agree.

 

11.6.

Indemnification and Contribution .

(a)             In the event of a registration of any Registrable Securities under the 1933 Act pursuant to Section 11, the Company will, to the extent permitted by law, indemnify and hold harmless the Seller, each officer of the Seller, each director of the Seller, each underwriter of such Registrable Securities thereunder and each other person, if any, who controls such Seller or underwriter within the meaning of the 1933 Act, against any losses, claims, damages or liabilities, joint or several, to which the Seller, or such underwriter or controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any registration statement under which such Registrable Securities were registered under the 1933 Act pursuant to Section 11, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances when made, and will subject to the provisions of Section 11.6(c) reimburse the Seller, each such underwriter and each such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable to the Seller to the extent that any such damages arise out of or are based upon an untrue statement or omission made in any preliminary prospectus if (i) the Seller failed to send or deliver a copy of the final prospectus delivered by the Company to the Seller with or prior to the delivery of written confirmation of the sale by the Seller to the person asserting the claim from which such damages arise, (ii) the final prospectus would have corrected such untrue statement or alleged untrue statement or such omission or alleged omission, or (iii) to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by any such Seller, or any such controlling person in writing specifically for use in such registration statement or prospectus.

(b)             In the event of a registration of any of the Registrable Securities under the 1933 Act pursuant to Section 11, each Seller severally but not jointly will, to the extent permitted by law, indemnify and hold harmless the Company, and each person, if any, who controls the Company within the meaning of the 1933 Act, each officer of the Company who signs the registration statement, each director of the Company, each underwriter and each person who controls any underwriter within the meaning of the 1933 Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director, underwriter or controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the registration statement under which such Registrable Securities were registered under the 1933 Act pursuant to Section 11, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such officer, director, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim,

 

16

 



 

damage, liability or action, provided, however, that the Seller will be liable hereunder in any such case if and only to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such Seller, as such, furnished in writing to the Company by such Seller specifically for use in such registration statement or prospectus, and provided, further, however, that the liability of the Seller hereunder shall be limited to the net proceeds actually received by the Seller from the sale of Registrable Securities covered by such registration statement.

(c)             Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 11.6(c) and shall only relieve it from any liability which it may have to such indemnified party under this Section 11.6(c), except and only if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 11.6(c) for any legal expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or if the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified parties, as a group, shall have the right to select one separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the indemnifying party as incurred.

(d)             In order to provide for just and equitable contribution in the event of joint liability under the 1933 Act in any case in which either (i) a Seller, or any controlling person of a Seller, makes a claim for indemnification pursuant to this Section 11.6 but it is judicially determined (by the entry of a judgment or decree by a court of competent jurisdiction ) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 11.6 provides for indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of the Seller or controlling person of the Seller in circumstances for which indemnification is not provided under this Section 11.6; then, and in each such case, the Company and the Seller will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that the Seller is responsible only for the portion represented by the percentage that the public offering price of its securities offered by the registration statement bears to the public offering price of all securities offered by such registration statement, provided, however, that, in any such case, (y) the Seller will not be required to contribute any amount in excess of the public offering price of all such securities sold or to be sold by it pursuant to such registration statement; and (z) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation.

 

17

 



 

 

 

11.7.

Delivery of Unlegended Shares .

(a)             Within three (3) business days (such third business day being the “ Unlegended Shares Delivery Date ”) after the business day on which the Company has received (i) a notice that Shares or Warrant Shares have been sold pursuant to a registration statement or Rule 144 under the 1933 Act, (ii) a representation that the prospectus delivery requirements, or the requirements of Rule 144, as applicable and if required, have been satisfied, and (iii) the original share certificates representing the shares of Common Stock that have been sold, and (iv) in the case of sales under Rule 144, customary representation letters of the Subscriber and/or Subscriber’s broker regarding compliance with the requirements of Rule 144, the Company at its expense, (y) shall deliver, and shall cause legal counsel selected by the Company to deliver to its transfer agent (with copies to Subscriber) an appropriate instruction and opinion of such counsel, directing the delivery of shares of Common Stock without any legends including the legend set forth in Section 4 above, reissuable pursuant to any effective and current Registration Statement described in Section 11 of this Agreement or pursuant to Rule 144 under the 1933 Act (the “ Unlegended Shares ”); and (z) cause the transmission of the certificates representing the Unlegended Shares together with a legended certificate representing the balance of the submitted Shares or Warrant Shares certificate, if any, to the Subscriber at the address specified in the notice of sale, via express courier, by electronic transfer or otherwise on or before the Unlegended Shares Delivery Date.

(b)             In lieu of delivering physical certificates representing the Unlegended Shares, if the Company’s transfer agent is participating in the Depository Trust Company (“ DTC ”) Fast Automated Securities Transfer program, upon request of a Subscriber, so long as the certificates therefor do not bear a legend and the Subscriber is not obligated to return such certificate for the placement of a legend thereon and the Subscriber has provided all required broker information to the Company and its transfer agent, the Company must cause its transfer agent to electronically transmit the Unlegended Shares by crediting the account of Subscriber’s prime Broker with DTC through its Deposit Withdrawal Agent Commission system. Such delivery must be made on or before the Unlegended Shares Delivery Date.

 

(c)             The Company understands that a delay in the delivery of the Unlegended Shares pursuant to Section 11 hereof after the Unlegended Shares Delivery Date could result in economic loss to Subscriber. As compensation to Subscriber for such loss, the Company agrees to pay late payment fees (as liquidated damages and not as a penalty) to the Subscriber for more than 2 business days’ late delivery of Unlegended Shares in the amount of $100 per business day after the Delivery Date for each $100,000 of Purchase Price of the Unlegended Shares subject to the delivery default. If during any 360 day period, the Company fails to deliver Unlegended Shares as required by this Section 11.7 for an aggregate of thirty (30) days, then each Subscriber or assignee holding Securities subject to such default may, at its option, require the Company to redeem all or any portion of the Shares or Warrant Shares subject to such default at a price per share equal to 120% of the Purchase Price of such Shares or Warrant Shares (“ Unlegended Redemption Amount ”).

 

(d)             In addition to any other rights available to a Subscriber, if the Company fails to deliver to a Subscriber the Unlegended Shares as required pursuant to this Agreement, within seven (7) business days after the Unlegended Shares Delivery Date and the Subscriber or a broker on the Subscriber’s behalf, purchases (in an open market transaction or otherwise) shares of common stock to deliver in satisfaction of a sale by such Subscriber of the shares of Common Stock which the Subscriber was entitled to receive from the Company (a "Buy-In"), then the Company shall pay in cash to the Subscriber (in addition to any remedies available to or elected by the Subscriber) the amount by which (A) the Subscriber's total purchase price (including brokerage commissions, if any) for the shares of common stock so purchased exceeds (B) the aggregate purchase price of the shares of Common Stock delivered to the Company for reissuance as Unlegended Shares together with interest thereon at a rate of 15% per annum, accruing until such amount and any accrued interest thereon is paid in full (which amount shall be

 

18

 



 

paid as liquidated damages and not as a penalty). For example, if a Subscriber purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to $10,000 of Purchase Price of shares of Common Stock delivered to the Company for reissuance as Unlegended Shares, the Company shall be required to pay the Subscriber $1,000, plus interest, less any excess from sale of the Unlegended Shares. The Subscriber shall provide the Company written notice and evidence indicating the amounts payable to the Subscriber in respect of the Buy-In.

 

(e)             In the event a Subscriber shall request delivery of Unlegended Shares as described in Section 11.7 and the Company is required to deliver such Unlegended Shares pursuant to Section 11.7, the Company may not refuse to deliver Unlegended Shares based on any claim that such Subscriber or any one associated or affiliated with such Subscriber has been engaged in any violation of law, or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery of such Unlegended Shares or exercise of all or part of said Warrant shall have been sought and obtained by the Company or at the Company’s request or with the Company’s assistance, and the Company has posted a surety bond for the benefit of such Subscriber in the amount of 120% of the amount of the Purchase Price of the Shares and Warrant Shares which are subject to the injunction or temporary restraining order, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Subscriber to the extent Subscriber obtains judgment in Subscriber’s favor.

 

12.            Trickle Out . Except as set forth on Schedule 12 hereto, each Subscriber agrees for itself and each of its Affiliates, that it and its Affiliates will not sell or transfer any Shares and Warrant Shares (collectively, “ Restricted Instruments ”) until the first anniversary of the Closing Date. During the forty-eight (48) month period immediately following the Closing Date (“ Trickle Out Period ”), each Subscriber agrees that it and its Affiliates will not transfer such number of Restricted Instruments in the first, second and third twelve month period in excess of the number which could result in gross proceeds to such Subscriber and its Affiliates in excess of 125%, 150% and 200% respectively of the amount of Purchase Price paid by the Subscriber for the Shares (“ Restricted Value ”). There are no sales restrictions imposed on Subscriber pursuant to this Section 12 after the fourth anniversary of the Closing Date. Notwithstanding the foregoing restrictions on transfer, the Subscriber may, at any time and from time to time, transfer the Restricted Instruments (i) as bona fide gifts or transfers by will or intestacy, (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the Holder, provided that any such transfer shall not involve a disposition for value, (iii) to a partnership which is the general partner of a partnership of which the Holder is a general partner and (iv) to an Affiliate of the Subscriber, provided, that, in the case of any such gift or transfer, each donee or transferee agrees in writing to be bound by the terms and conditions contained in this Section 12 in the same manner as such terms and conditions apply to the Subscriber. For purposes hereof, "immediate family" means any relationship by blood, marriage or adoption, not more remote than first cousin. The Company may request certification from the Subscriber and its Affiliates that Subscriber and its Affiliates have complied with the provisions of this Section 12. Each Subscriber and its Affiliates, transferees and assigns will be deemed a single entity when determining the Restricted Value applicable to such Subscriber, and its Affiliates, transferees and assigns. The Company may not release any Subscriber from the restrictions in this Section 12 unless it releases all Subscribers from these restrictions on a pari passu basis based on the initial amount of Shares purchased hereunder by all Subscribers. The Company may not modify or waive the restrictions set forth on Schedule 12 without the consent of 75% of the Subscribers who hold Shares, Warrants or Warrant Shares at the effective time of such modification or waiver.

 

13.

Miscellaneous .

(a)             Notices . All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein,

 

19

 



 

shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be: (i) if to the Company, to: Pluristem Life Systems, Inc., MATAM Advanced Technology Park, Building No. 20, Haifa, Israel 31905, telecopier: 011-972-4-850-1085, with an additional copy by telecopier only to: Clark Wilson LLP, 800-885 West Georgia Street, Vancouver, B.C. Canada, Attn: Bernard Pinsky, Esq., telecopier: (604) 687-6314, and (ii) if to the Subscribers, to: the one or more addresses and telecopier numbers indicated on the signature pages hereto, with an additional copy by telecopier only to: Grushko & Mittman, P.C., 551 Fifth Avenue, Suite 1601, New York, New York 10176, telecopier: (212) 697-3575.

(b)            Entire Agreement; Assignment . This Agreement and other documents delivered in connection herewith represent the entire agreement between the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties. Neither the Company nor the Subscribers have relied on any representations not contained or referred to in this Agreement and the documents delivered herewith. No right or obligation of the Company shall be assigned without prior notice to and the written consent of the Subscribers.

(c)              Counterparts/Execution . This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same instrument. This Agreement may be executed by facsimile signature and delivered by facsimile transmission.

(d)            Law Governing this Agreement . This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state of New York. The parties and the individuals executing this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.

(e)             Specific Enforcement, Consent to Jurisdiction . The Company and Subscriber acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which any of them may be entitled by law

 

20

 



 

or equity. Subject to Section 13(d) hereof, each of the Company, Subscriber and any signator hereto in his personal capacity hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction in New York of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Nothing in this Section shall affect or limit any right to serve process in any other manner permitted by law.

(f)             Independent Nature of Subscribers .   The Company acknowledges that the obligations of each Subscriber under the Transaction Documents are several and not joint with the obligations of any other Subscriber, and no Subscriber shall be responsible in any way for the performance of the obligations of any other Subscriber under the Transaction Documents.  The Company acknowledges that the decision of each Subscriber to purchase Securities has been made by such Subscriber independently of any other Subscriber and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition (financial or otherwise) or prospects of the Company which may have been made or given by any other Subscriber or by any agent or employee of any other Subscriber, and no Subscriber or any of its agents or employees shall have any liability to any Subscriber (or any other person) relating to or arising from any such information, materials, statements or opinions.  The Company acknowledges that nothing contained in any Transaction Document, and no action taken by any Subscriber pursuant hereto or thereto (including, but not limited to, the (i) inclusion of a Subscriber in the Registration Statement and (ii) review by, and consent to, such Registration Statement by a Subscriber) shall be deemed to constitute the Subscribers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Subscribers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.  The Company acknowledges that each Subscriber shall be entitled to independently protect and enforce its rights, including without limitation, the rights arising out of the Transaction Documents, and it shall not be necessary for any other Subscriber to be joined as an additional party in any proceeding for such purpose.  The Company acknowledges that it has elected to provide all Subscribers with the same terms and Transaction Documents for the convenience of the Company and not because Company was required or requested to do so by the Subscribers.  The Company acknowledges that such procedure with respect to the Transaction Documents in no way creates a presumption that the Subscribers are in any way acting in concert or as a group with respect to the Transaction Documents or the transactions contemplated thereby.

(g)            Consent . As used in the Agreement, “consent of the Subscribers” or similar language means the consent of holders of not less than 80% of the total of the Shares owned by Subscribers on the date consent is requested.

(h)            Equal Treatment . No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered and paid to all the Subscribers and their permitted successors and assigns.

(i)             Maximum Payments . Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to the Subscriber and thus refunded to the Company.

 

(j)            Calendar Days . All references to “days” in the Transaction Documents shall mean calendar days unless otherwise stated. The terms “business days” and “trading days” shall

 

21

 



 

mean days that the New York Stock Exchange is open for trading for three or more hours. Time periods shall be determined as if the relevant action, calculation or time period were occurring in New York City.

 

 

22

 



 

 

SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT (A)

 

Please acknowledge your acceptance of the foregoing Subscription Agreement by signing and returning a copy to the undersigned whereupon it shall become a binding agreement between us.

 

PLURISTEM LIFE SYSTEMS, INC.

a Nevada corporation

 

 

By:_________________________________

Name: Zami Aberman

Title: CEO

 

Dated: March ____, 2007

 

 

SUBSCRIBER

PURCHASE PRICE

 

Name of Subscriber: ____________________________________

 

_____________________________________________________

 

Address: _____________________________________________

 

____________________________________________________

 

Fax No.: ____________________________________________

 

Taxpayer ID# (if applicable): ____________________________

 

 

 

____________________________________________________

(Signature)

By:

 

 

 

 

 

23

 



 

 

LIST OF EXHIBITS AND SCHEDULES

 

 

Exhibit A

Form of Warrant

 

Exhibit B

Company Account

 

Exhibit C

Form of Legal Opinion

 

Schedule 5(d)

Additional Issuances/Capitalization

 

Schedule 5(m)

Undisclosed Liabilities

 

Schedule 5(v)

Transfer Agent

 

Schedule 12

Trickle Out Exceptions

 

 

24

 



 

 

EXHIBIT B

Wire Instructions to Company Account

 

Bank Leumi Ltd.

Branch 864

Swift Code: LUMIILIT864

Eban: IL0108642214007

For the Account of: Pluristem Life Systems, Inc.

Account Number: 22140077

 

 

25

 



 

 

SCHEDULE 12

TRICKLE OUT EXCEPTIONS

 

The holding period of 30,500,000 common stock purchase warrants (“ Honig Warrants ”) issued to Barry Honig (“ Honig ”) as of January 26 ___, 2007, for purposes of Rule 144 under the 1933 Act shall be deemed to have commenced as of January 26 ___, 2007 and in connection with the investment in shares of Common Stock purchased pursuant to this Subscription Agreement, payment for which was made to the Company on January 26, 2007. The Honig Warrants constitute a component of Honig’s Restricted Instruments. Honig agrees by his signature to the Subscription Agreement, for himself and all other holders of Honig’s Restricted Instruments that during the Trickle Out Period, Honig and Honig’s Affiliates will not sell on any Trading Day an amount of shares of Common Stock in excess of ten percent (10%) of the trading volume as reported by Bloomberg LP for the Principal Market for such Trading Day. The Restricted Value applicable to Honig in connection with the Restricted Instruments shall be $1,250,000.

 

 

26

 



 

 

Schedule 5(d)

Additional Issuances/Capitalization

 

 

 

 

 

Item

Amount

Remarks

 

Share capital

288,044,317

As of May 14, 2007

 

Warrants

29,245,546

Issued April 2006 and before

 

ESOP 2003

4,100,000

Including SAB and consultants

 

ESOP 2005

380,000,000

Including SAB and consultants

 

 

27

 



 

 

Schedule 5 (m)

 

The Company is in breach of its requirement under a $3,000,000 Convertible Debenture private placement Registration Rights Agreement dated April 3, 2006, to keep a registration statement registering the shares and warrants issuable on conversion of the Convertible Debentures effective for a “period continuing until the earlier of (i) the date when the Investors may sell all the Regisratble Securities under Rule 144 without volume or other restrictions or limits or (ii) the date when the Investors no longer own any of the Registrable Securities...”. The Company is currently undertaking the preparation and filing of a registration statement intended to remedy this breach.

 

 

28

 



 

 

Schedule 5 (v)

 

Grace Deer-Loiseau

American Stock Transfer & Trust Company

6201 15th Avenue, 2nd Floor

Brooklyn, NY  11219

Tel: (718) 921-8247

Fax (718) 921-8323

e-mail: gdeer-lois@amstock.com

Team members: Wilbert Myles & Angelia Francis-Brown

Team e-mail: admin4@amstock.com

 

 

29